FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Bonaventura Clotet

Research Profile

Disorders

HIV Infections

Living Beings

HIV-1
HIV

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Anatomy

CD4-Positive T-Lymphocytes

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Eduardo Pauls; Ruth Peña; Marc Permanyer; Eva Riveiro-Muñoz; Alba Ruiz; Bonaventura Clotet; Helena Costa; José A Esté; Esther Jimenez; Miguel A Martinez; Rute Nascimiento; R Michael Parkhouse; Ester Ballana; Margarida Bofill
Restriction of HIV-1 Replication in Primary Macrophages by IL-12 and IL-18 through the Upregulation of SAMHD1.
Ester Ballana; Christian Brander; Maria Casadellà; Bonaventura Clotet; Miguel Angel Martínez; Marc Noguera; Roger Paredes; Mariona Parera; Christian Pou; Eva Riveira-Munoz; José R Santos; Vanessa Bach; Roger Badia; José A Esté
HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32.
Cristina Tintori; Roger Badia; Bonaventura Clotet; José A Esté; Manikandan Selvaraj; Maurizio Botta
Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Bonaventura Clotet (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Eduardo Pauls; Ruth Peña; Marc Permanyer; Eva Riveiro-Muñoz; Alba Ruiz; Bonaventura Clotet; Helena Costa; José A Esté; Esther Jimenez; Miguel A Martinez; Rute Nascimiento; R Michael Parkhouse; Ester Ballana; Margarida Bofill
Restriction of HIV-1 Replication in Primary Macrophages by IL-12 and IL-18 through the Upregulation of SAMHD1.
Journal of immunology (Baltimore, Md. : 1950) 2013;190(9):4736-41.
2013: Ester Ballana; Christian Brander; Maria Casadellà; Bonaventura Clotet; Miguel Angel Martínez; Marc Noguera; Roger Paredes; Mariona Parera; Christian Pou; Eva Riveira-Munoz; José R Santos; Vanessa Bach; Roger Badia; José A Esté
HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32.
Immunobiology 2013;218(4):543-7.
2013: Cristina Tintori; Roger Badia; Bonaventura Clotet; José A Esté; Manikandan Selvaraj; Maurizio Botta
Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120.
ChemMedChem 2013;8(3):475-83.
2013: Joseph J Eron; Tamio Fujiwara; Jenny Huang; Christine Katlama; Princy Kumar; Adriano Lazzarin; Sherene Min; Isabelle Poizot-Martin; Gary Richmond; Vincent Soriano; Cindy Vavro; Jane Yeo; Mounir Ait-Khaled; Bonaventura Clotet; Jacques Durant
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.
The Journal of infectious diseases 2013;207(5):740-8.
2013: K Theys; C Torti; Anne-Mieke Vandamme; J Vercauteren; M Zazzi; Ricardo Camacho; Bonaventura Clotet; Andrea De Luca; Z Grossman; E Schülter; Joke Snoeck; A Sönnerborg; D Struck; Ana Abecasis
HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.
Antimicrobial agents and chemotherapy 2013;57(2):1053-6.
2013: Felipe García; Josep M Gatell; Cristina Gil; Alberto C Guardo; Agathe León; Jeffrey D Lifson; Javier Martínez-Picado; Montserrat Plana; Brigitte Autran; Nuria Climent; Bonaventura Clotet; Judit Dalmau; Teresa Gallart
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.
Science translational medicine 2013;5(166):166ra2.
2013: Jurgen Vercauteren; Maurizio Zazzi; Eric Van Wijngaerden; Anne-Mieke Vandamme; Gertjan Beheydt; Ricardo Camacho; Bonaventura Clotet; Andrea De Luca; Anna Maria Geretti; Zehava Grossman; Stijn Imbrechts; Rolf Kaiser; Pieter Libin; Mattia Prosperi; Jean-Claude Schmit; Anders Sönnerborg; Carlo Torti; Kristel Van Laethem
Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response.
PloS one 2013;8(4):e61436.
2013: Maria T Rodriguez-Plata; Maria C Puertas; Isabel Puigdomènech; Julià Blanco; Jorge Carrillo; Bonaventura Clotet; Itziar Erkizia; Nuria Izquierdo-Useros; Javier Martinez-Picado
The infectious synapse formed between mature dendritic cells and CD4+ T cells is independent of the presence of the HIV-1 envelope glycoprotein.
Retrovirology 2013;10():42.
2013: Marta Curriu; Ana M Garcia-Quintana; Marta Massanella; Eugènia Negredo; Jordi Puig; Josepa Rigau; Cecilia Cabrera; Jorge Carrillo; Jesus Castro-Marrero; Bonaventura Clotet; José Alegre; Julià Blanco
Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome.
Journal of translational medicine 2013;11():68.
2013: Anuska Llano; Silvia Marfil; Beatriz Mothe; Lidia Ruiz; Víctor Sánchez; Eloísa Yuste; Julià Blanco; Jorge Carrillo; Bonaventura Clotet; Elisabet García; Christian Brander
Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions.
Journal of translational medicine 2013;11():48.
2013: Sebastián Videla; M Paz Cañadas; Bonaventura Clotet; Patricia Cobarsi; Josep Coll; Laila Darwich; Francesc García-Cuyás; Rafael A Molina-Lopez; Marta Piñol; Guillem Sirera
Natural history of human papillomavirus infections involving anal, penile, and oral sites among HIV-positive men.
Sexually transmitted diseases 2013;40(1):3-10.
2012: Maria C Puertas; Peter Van Den Eede; Julia G Prado; Mònica Ballestero; Maria J Buzón; Bonaventura Clotet; Javier Martinez-Picado
Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.
Journal of clinical microbiology 2012;50(12):3909-16.
2012: Elena Capel; Bonaventura Clotet; Glòria Martrus; Mariona Parera; Miguel Angel Martínez
Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness.
The Journal of general virology 2012;93(Pt 12):2625-34.
2012: Marta Massanella; Eugenia Negredo; Núria Pérez-Álvarez; Maria Carmen Puertas; Jordi Puig; Maria J Buzón; Jorge Carrillo; Bonaventura Clotet; Javier Martínez-Picado; Julià Blanco
Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
AIDS (London, England) 2012;26(18):2285-93.
2012: Maria Saumoy; Esteban Ribera; José Luis Sánchez-Quesada; Bonaventura Clotet; Adrian Curran; Jordi Curto; Josep Maria Gatell; Hernando Knobel; Josep Maria Llibre; Esteban Martínez; Margarita Masó; Jordi Ordoñez-Llanos; Daniel Podzamczer
LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.
Atherosclerosis 2012;225(1):200-7.
2012: Bonaventura Clotet; Ravindra Kumar Gupta; Andrew Hill; Yvon van Delft; Christiane Moecklinghoff
Interpretation of resistance data from randomized trials of first-line antiretroviral treatment.
AIDS reviews 2012;14(4):247-55.
2012: Anna Bonjoch; Bonaventura Clotet; Patricia Echeverría; Carla Estany; Núria Perez-Alvarez; Jordi Puig; Eugenia Negredo
High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.
Antiviral research 2012;96(1):65-9.
2012: José Moltó; Eugenia Negredo; Marta Valle; Samandhy Cedeño; Cristina Miranda; Bonaventura Clotet
Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients.
Antimicrobial agents and chemotherapy 2012;56(10):5328-31.
2012: Ramon Sanmartin; Arantza Sanvicens; Jordi Tor; Eva Barluenga; Bonaventura Clotet; Elena de Felipe; Antoni Jou; Juan José López; Elisenda Martinez; Robert Muga; Isabel Ojanguren; Cristina Tural
Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.
AIDS research and human retroviruses 2012;28(10):1235-43.
2012: L Darwich; F García-Cuyás; Mariona Llatjos; R A Molina-López; M Piñol; Guillem Sirera; S Vela; Sebastián Videla; M Paz Cañadas; Bonaventura Clotet; P Cobarsi; J Coll
Condylomata, cytological abnormalities and human papillomavirus infection in the anal canal in HIV-infected men.
HIV medicine 2012;13(9):549-57.
2012: Sandra Franco; Bonaventura Clotet; Cristina Tural; Miguel A Martinez
Alleles at rs4273729 in the chromosome 6 do not predict response to peg-interferon-α and ribavirin therapy in hepatitis C virus/HIV-1-coinfected patients.
AIDS (London, England) 2012;26(15):1973-4.
2012: Marc Permanyer; Eduardo Pauls; Roger Badia; Ester Ballana; Bonaventura Clotet; José A Esté
Trans-infection but not infection from within endosomal compartments after cell-to-cell HIV-1 transfer to CD4+ T cells.
The Journal of biological chemistry 2012;287(38):32017-26.
2012: Laia Ros-Blanco; Luis Ruíz-Ávila; Joan Seoane; Jordi Teixidó; Ramon Bosser; Bonaventura Clotet; José A Esté; Ana Kosoy; Judit Anido; José I Borrell
Noncyclam tetraamines inhibit CXC chemokine receptor type 4 and target glioma-initiating cells.
Journal of medicinal chemistry 2012;55(17):7560-70.
2012: Ester Ballana; Christian Brander; Bonaventura Clotet; Margarita del Val; Eulalia Grau; Beatriz Mothe; Eva Ramirez de Arellano; Alba Ruiz-de Andres; Francisco Aguilar; Roger Badia; José A Esté
Differential prevalence of the HLA-C -- 35 CC genotype among viremic long term non-progressor and elite controller HIV+ individuals.
Immunobiology 2012;217(9):889-94.
2012: Marc Permanyer; Eva Riveira-Munoz; Alba Ruiz; Encarna Gonzalo; Roger Badia; Ester Ballana; Bonaventura Clotet; José A Esté
Antiretroviral agents effectively block HIV replication after cell-to-cell transfer.
Journal of virology 2012;86(16):8773-80.
2012: Raimon Puig-de-la-Bellacasa; José I Borrell; Bonaventura Clotet; José A Esté; Laura Giménez; Encarna Gonzalo; Rosalia Pascual; Sofia Pettersson; Jordi Teixidó
Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.
European journal of medicinal chemistry 2012;54():159-74.
2012: Javier A Estévez; Maria A Mangues; José Moltó; Montserrat Puntes; Laura Tuneu; Rosa Antonijoan; Manuel J Barbanoj; Samandhy Cedeño; Bonaventura Clotet; Pere Domingo; Marta Valle
Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.
The Journal of antimicrobial chemotherapy 2012;67(8):2013-9.
2012: Giuseppe La Regina; giovanni maga; Ettore Novellino; Francesco Piscitelli; Alberta Samuele; Dominique Schols; Andrea Brancale; Bonaventura Clotet; Antonio Coluccia; Sandro Cosconati; José A Esté; Valeria Famiglini; Emmanuel Gonzalez; Romano Silvestri
New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
Journal of medicinal chemistry 2012;55(14):6634-8.
2012: Josep M Llibre; Bonaventura Clotet
Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment.
AIDS reviews 2012;14(3):168-78.
2012: M Paz Cañadas; Vincenzo Cirigliano; Bonaventura Clotet; Josep Coll; Laila Darwich; Guillermo Sirera; Sebastián Videla
Comparison of the f-HPV typing™ and Hybrid Capture II® assays for detection of high-risk HPV genotypes in cervical samples.
Journal of virological methods 2012;183(1):14-8.
2012: Francesc Cunyat; Marta Curriu; Elisabet García; Silvia Marfil; Julià Blanco; Bonaventura Clotet; Cecilia Cabrera
Evaluation of the cytopathicity (fusion/hemifusion) of patient-derived HIV-1 envelope glycoproteins comparing two effector cell lines.
Journal of biomolecular screening 2012;17(6):727-37.
2012: Maria T Rodriguez-Plata; Alejandra Urrutia; Arnaud Moris; Julia G Prado; Maria Carmen Puertas; Maria J Buzón; Sylvain Cardinaud; Samandhy Cedeño; Bonaventura Clotet; Pierre-Grégoire Coulon; Itziar Erkizia; Nuria Izquierdo-Useros; Javier Martinez-Picado
HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T cell activation.
Journal of immunology (Baltimore, Md. : 1950) 2012;188(12):6036-45.
2012: Eulàlia Pinyol; Bonaventura Clotet; Jose A Esté; Silvia Frutos; Ernest Giralt; Dolors Grillo-Bosch; Anna Diez
Applications of 3-aminolactams: design, synthesis, and biological evaluation of a library of potential dimerisation inhibitors of HIV1-protease.
Organic & biomolecular chemistry 2012;10(22):4348-54.
2012: Antonio Javier Blasco; Vicente Boix; Bonaventura Clotet; Pere Domingo; Josep M Gatell; Juan González-García; Hernando Knobel; Pablo Lázaro; Josep M Llibre; Juan Carlos López; Fernando Lozano; José M Miró; Daniel Podzamczer; Juan Miguel Santamaría; Montserrat Tuset; Laura Zamora; José Ramón Arribas
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
Enfermedades infecciosas y microbiología clínica 2012;30(6):283-93.
2012: José R Santos; Jonathan M Schapiro; Bonaventura Clotet; Pere Domingo; María José Galindo; Arkaitz Imaz; José A Iribarren; Josep M Llibre; Ana Mariño; Celia Miralles; Santiago Moreno; Arelly Ornelas
Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.
The Journal of antimicrobial chemotherapy 2012;67(6):1462-9.
2012: José Moltó; Eugenia Negredo; Marta Valle; Samandhy Cedeño; Cristina Miranda; Bonaventura Clotet
Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients.
Antimicrobial agents and chemotherapy 2012;56(6):2837-41.
2012: Guillem Sirera; Sebastián Videla; MariPaz Cañadas; Emanuela d'Angelo; Laila Darwich; Bonaventura Clotet
A surprising evolution from oral human papillomavirus 16 infection to lymph node metastasis of tonsilar squamous cell carcinoma in an HIV-infected patient.
AIDS (London, England) 2012;26(8):1044-5.
2012: Marco Radi; Alberta Samuele; Silvia Schenone; Claudio Zamperini; Gianni Casaluce; Daniele Castagnolo; Bonaventura Clotet; Elena Dreassi; José A Esté; Luigi Franchi; Encarna Gonzalo; giovanni maga; Mafalda Pagano; Maurizio Botta
Synthesis, biological activity, and ADME properties of novel S-DABOs/N-DABOs as HIV reverse transcriptase inhibitors.
ChemMedChem 2012;7(5):883-96.
2012: Calvin J Cohen; Herta Crauwels; Jan Fourie; Beatriz Grinsztejn; Margaret A Johnson; Eric Lefebvre; Jean-Michel Molina; Laurence Rimsky; Michael Saag; Khuanchai Supparatpinyo; Simon Vanveggel; Peter Williams; Hao Wu; Katia Boven; Pedro Cahn; Bonaventura Clotet
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
Journal of acquired immune deficiency syndromes (1999) 2012;60(1):33-42.
2012: Carmina R Fumaz; Marian Gonzalez-Garcia; Anuska Llano; Beatriz Mothe; Jose Munoz-Moreno; Nuria Perez-Alvarez; Jordi Puig; Xavier Borras; Christian Brander; Jordi Fernandez-Castro; Maria José Ferrer; Bonaventura Clotet
Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment.
Brain, behavior, and immunity 2012;26(4):568-72.
2012: dante rotili; Alberta Samuele; Domenico Tarantino; Ludovica Morera; Ira Musmuca; Maxim B Nawrozkij; Marco Pierini; Rino Ragno; Marino Artico; FLAVIO BALLANTE; Giorgia Botta; Roberto Cirilli; Bonaventura Clotet; José A Esté; Emmanuel Gonzalez; giovanni maga; Antonello Mai
2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
Journal of medicinal chemistry 2012;55(7):3558-62.
2012: Juan Macías; Josep Mallolas; Santiago Moreno; Karin Neukam; Enrique Ortega; Juan A Pineda; José A Cartón; Bonaventura Clotet; Manell Crespo; Ignacio de Los Santos; Pere Domingo; José A Iribarren; María J Jiménez-Expósito; Hernando Knobel; Luis Lopez-Cortes
Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.
HIV clinical trials 2012;13(2):61-9.
2012: Ester Ballana; Bonaventura Clotet; Encarna Gonzalo; Eulàlia Grau; José A Iribarren; José A Este
Rare LEDGF/p75 genetic variants in white long-term nonprogressor HIV+ individuals.
AIDS (London, England) 2012;26(4):527-8.
2012: José Moltó; Marta Valle; Antonia Andreu; Xavier Bonafont; Sara Malo; Cristina Miranda; Bonaventura Clotet
[Use of herbal remedies among HIV-infected patients: patterns and correlates].
Medicina clínica 2012;138(3):93-8.
2012: Juan A Pineda; Josep Mallolas; Santiago Moreno; Karin Neukam; Enrique Ortega; José A Cartón; Bonaventura Clotet; Manuel Crespo; Ignacio de Los Santos; Pere Domingo; José A Iribarren; María J Jiménez-Expósito; Hernando Knobel; Luis Lopez-Cortes; Juan Macías
Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.
The Journal of infection 2012;64(2):204-11.
2012: Nuria Izquierdo-Useros; Oliver T Keppler; Hans-Georg Kräusslich; Maier Lorizate; Bonaventura Clotet; Elina Erikson; Itziar Erkizia; Bärbel Glass; Maria Pino; Maria C Puertas; Maria T Rodriguez-Plata; Amalio Telenti; Nadine Zangger; Javier Martinez-Picado
Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides.
PLoS biology 2012;10(12):e1001448.
2012: Eugenia Negredo; Nuria Perez-Alvarez; Jordi Puig; Joaquin Rosales; Luís del Rio; Silvana di Gregorio; Carla Estany; Guadalupe Gómez; Moisés Gómez-Mateu; Anna Bonjoch; Bonaventura Clotet
Time of progression to osteopenia/osteoporosis in chronically HIV-infected patients: screening DXA scan.
PloS one 2012;7(10):e46031.
2012: Mariona Parera; Gloria Martrus; Bonaventura Clotet; Sandra Franco; Miguel Angel Martinez
Canine hepacivirus NS3 serine protease can cleave the human adaptor proteins MAVS and TRIF.
PloS one 2012;7(8):e42481.
2012: José R Santos; Isabel Bravo; Bonaventura Clotet; Josep M Llibre; José Moltó; Eugenia Negredo; Arelly Ornelas; Roger Paredes
Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.
PloS one 2012;7(5):e37442.
2012: Marta Curriu; Elisabet Garcia; Marta Massanella; Ruth Peña; Peter Wienberg; Joan Areal; Julià Blanco; Margarita Bofill; Cristina Carrato; Jorge Carrillo; Bonaventura Clotet; Francesc Cunyat; Cecilia Cabrera
Susceptibility of human lymphoid tissue cultured ex vivo to xenotropic murine leukemia virus-related virus (XMRV) infection.
PloS one 2012;7(5):e37415.
2012: Judith Dalmau; Itziar Erkizia; Javier Martinez-Picado; Roger Paredes; Maria Pino; Christian Pou; Bonaventura Clotet; Francisco M Codoñer; Julia G Prado
In-depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection.
PloS one 2012;7(2):e32714.
2012: Francesc Cunyat; Marta Curriu; Elisabet García; Silvia Marfil; Nuria Pérez-Alvárez; Carlo Federico Perno; Valentina Svicher; Julià Blanco; Bonaventura Clotet; Cecilia Cabrera
The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.
Retrovirology 2012;9():15.
2012: Montserrat de Castellarnau; Sandra Franco; Ester Aparicio; Bonaventura Clotet; Mariona Parera; Cristina Tural; Miguel Angel Martínez
Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
PloS one 2012;7(2):e31016.
2012: Marta Curriu; Patrice Debré; Hughes Fausther-Bovendo; Cecilio López-Galíndez; Marta Massanella; María Pernas; Vincent Vieillard; Cecilia Cabrera; Jorge Carrillo; Bonaventura Clotet; Julià Blanco
Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function.
PloS one 2012;7(2):e30330.
2012: Vicens Diaz-Brito; Pere Domingo; Felipe García; Josep M Gatell; Hernando Knobel; Agathe León; Joaquim Peraire; Joan Albert Arnaiz; Bonaventura Clotet; Anna Cruceta; David Dalmau
Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
Antiviral therapy 2012;17(2):337-46.
2012: Josep M Llibre; Javier Martinez-Picado; Marta Massanella; Sarah Palmer; Maria C Puertas; Mario Stevenson; Viktor Dahl; Pere Domingo; Anna Esteve; Josep M Gatell; Mar Gutierrez; Maria Larrouse; Julià Blanco; Maria J Buzón; Bonaventura Clotet
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Antiviral therapy 2012;17(2):355-64.
2012: Jean-Michel Molina; Lijie Zhong; Jaime Andrade-Villanueva; Andrew K Cheng; Steven L Chuck; Bonaventura Clotet; Nathan Clumeck; Anthony Lamarca; Ya-Pei Liu; Nicolas A Margot
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
The Lancet infectious diseases 2012;12(1):27-35.
2012: Alessandro Cozzi-Lepri; Jesper Kjaer; G Kronborg; Jens D Lundgren; Andrew N Phillips; Viktor von Wyl; J R Bogner; A Castagna; Bonaventura Clotet
The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.
HIV medicine 2012;13(1):62-72.
2011: Emmanuel González-Ortega; Roger Badia; Ester Ballana; Bonaventura Clotet; José A Esté
Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1.
Antiviral research 2011;92(3):479-83.
2011: Antonio Javier Blasco; Bonaventura Clotet; Pere Domingo; José Ramón Arribas; Juan González-García; Pablo Lázaro; Josep M Llibre; Juan Carlos López-Bernaldo; Fernando Lozano; Daniel Podzamczer; Juan Miguel Santamaría; Montserrat Tuset; Laura Zamora; Josep M Gatell
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].
Enfermedades infecciosas y microbiología clínica 2011;29(10):721-30.
2011: Gerard Minuesa; Marçal Pastor-Anglada; Bonaventura Clotet; Isabel Huber-Ruano; Hermann Koepsell; Javier Martinez-Picado
Drug uptake transporters in antiretroviral therapy.
Pharmacology & therapeutics 2011;132(3):268-79.
2011: Laila Darwich; Jordi Delas; Inés Fernández; Pilar Forcada; Mariona Llatjós; Guillem Sirera; Francesc Alameda; María-Paz Cañadas; Bonaventura Clotet; Josep Coll; Sebastià Videla
Human papillomavirus genotype distribution and human papillomavirus 16 and human papillomavirus 18 genomic integration in invasive and in situ cervical carcinoma in human immunodeficiency virus-infected women.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011;21(8):1486-90.
2011: Maria Nevot; Gloria Martrus; Bonaventura Clotet; Miguel Angel Martínez
RNA interference as a tool for exploring HIV-1 robustness.
Journal of molecular biology 2011;413(1):84-96.
2011: Maria J Buzón; Bonaventura Clotet; Francisco M Codoñer; Judith Dalmau; Simon D W Frost; Josep M Llibre; Marta Massanella; Roger Paredes; Christian Pou; Maria C Puertas; Mario Stevenson; Julià Blanco; Javier Martinez-Picado
Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
PLoS pathogens 2011;7(10):e1002314.
2011: Arkaitz Imaz; Josep M Llibre; Bonaventura Clotet; Esteban Ribera; Daniel Podzamczer
The role of inactive nucleoside/nucleotide reverse transcriptase inhibitors in salvage therapy for drug-resistant HIV-1 infection in the era of new classes and new generation antiretrovirals.
Journal of acquired immune deficiency syndromes (1999) 2011;58(2):e46-8.
2011: S Franco; Montserrat García-Retortillo; R Paredes; R Solà; Cristina Tural; E Aparicio; R Bellido; N Cañete; Bonaventura Clotet; M A Martínez
Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
Journal of viral hepatitis 2011;18(10):e578-82.
2011: Josep M Llibre; Fernando Lozano; Santiago Moreno; Antonio Rivero; José R Santos; José R Arribas; Bonaventura Clotet; Pere Domingo; Josep M Gatell
Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy.
AIDS (London, England) 2011;25(14):1683-90.
2011: Roger Paredes; Christian Pou; Maria Carmen Puertas; Wendy Bannister; Dénes Bánhegyi; Rocío Bellido; Gilberto Betancor; Johannes Bogner; Bonaventura Clotet; Alessandro Cozzi-Lepri; Panagiotis Gargalianos; Mónica Kisic; Jens Lundgren; Javier Martinez-Picado; Luis Menéndez-Arias
A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
The Journal of infectious diseases 2011;204(5):741-52.
2011: Emmanuel Gonzalez; Ester Ballana; Bonaventura Clotet; José A Esté
Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
AIDS (London, England) 2011;25(13):1557-83.
2011: Cristina Gil; Carmen Hurtado; Agathe León; Jeffrey D Lifson; Javier Martinez-Picado; L Miralles; José M Miró; Sara Nieto-Márquez; Tomás Pumarola; Cristina Rovira; Laura Zamora; Manel Almela; Christian Brander; Nuria Climent; Bonaventura Clotet; Judith Dalmau; Teresa Gallart; Felipe García; M Teresa García; José M Gatell
Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines.
Vaccine 2011;29(34):5711-24.
2011: Sonsoles Sánchez-Palomino; Eloísa Yuste; José Alcamí; Margarita Bofill; Jorge Carrillo; Bonaventura Clotet; Ana García; Felipe García; Josep M Gatell; Nuria González; Marta Massanella; Alberto Merino; Julià Blanco
A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity.
Vaccine 2011;29(32):5250-9.
2011: Calvin J Cohen; Herta Crauwels; Jan Fourie; Margaret A Johnson; Laurence Rimsky; Kiat Ruxrungtham; Simon Vanveggel; Hao Wu; Carmen Zorrilla; Jaime Andrade-Villanueva; Katia Boven; Bonaventura Clotet
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Lancet 2011;378(9787):229-37.
2011: Montserrat Plana; Felipe Garcia; Laila Darwich; Joan Romeu; Anna López; Cecilia Cabrera; Marta Massanella; Esther Canto; Raul Ruiz-Hernandez; Julià Blanco; Marcelo Sánchez; Josep M Gatell; Bonaventura Clotet; Lidia Ruiz; Margarita Bofill
The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses.
Immunology 2011;133(3):318-28.
2011: José R Santos; Sebastián Videla; Isabel Bravo; Pere Domingo; Elena Ferrer; Arkaitz Imaz; Josep M Llibre; Daniel Podzamczer; Esteban Ribera; Bonaventura Clotet
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
AIDS research and human retroviruses 2011;27(7):713-7.
2011: Ester Aparicio; Sandra Franco; Mariona Parera; Cristina Andrés; Cristina Tural; Bonaventura Clotet; Miguel Angel Martínez
Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
Journal of virology 2011;85(12):5961-9.
2011: Soumi Gupta; Johan Vingerhoets; Signe Fransen; Lotke Tambuyzer; Hilde Azijn; Arne Frantzell; Roger Paredes; Eoin Coakley; Steven Nijs; Bonaventura Clotet; Christos J Petropoulos; Jonathan Schapiro; Wei Huang; Gaston Picchio
Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.
Antimicrobial agents and chemotherapy 2011;55(6):2872-9.
2011: Maria José Buzón; Bonaventura Clotet; Eoin Coakley; Francisco M Codoñer; Judith Dalmau; Pham Phung; Terri Wrin; Anna Bonjoch; Javier Martinez-Picado
Combined antiretroviral therapy and immune pressure lead to in vivo HIV-1 recombination with ancestral viral genomes.
Journal of acquired immune deficiency syndromes (1999) 2011;57(2):109-17.
2011: Linda Wittkop; Andrea Antinori; Hannah Castro; Geneviève Chêne; Bonaventura Clotet; Céline Colin; Alessandro Cozzi-Lepri; Andrea de Luca; Frank de Wolf; David Dunn; Federico García; Huldrych F Günthard; Ali Judd; Jesper Kjaer; Claudia Kücherer; Jens D Lundgren; Bernard Masquelier; Niels Obel; Roger Paredes; Andrew Phillips; Deenan Pillay; Kholoud Porter; Anton Pozniak; Christoph Stephan; Rodolphe Thiébaut; Carlo Torti; Ard I van Sighem; Viktor von Wyl
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.
The Lancet infectious diseases 2011;11(5):363-71.
2011: dante rotili; Alberta Samuele; Domenico Tarantino; Maxim B Nawrozkij; Marino Artico; Bonaventura Clotet; José A Esté; Emmanuel Gonzalez-Ortega; giovanni maga; Antonello Mai
Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
Journal of medicinal chemistry 2011;54(8):3091-6.
2011: Wendy P Bannister; Alessandro Cozzi-Lepri; Jesper Kjær; Bonaventura Clotet; Adriano Lazzarin; Jean-Paul Viard; Gitte Kronborg; Dan Duiculescu; Marek Beniowski; Ladislav Machala; Andrew Phillips
Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.
The Journal of antimicrobial chemotherapy 2011;66(4):901-11.
2011: Jacob Nattermann; Martin Vogel; Hans Dieter Nischalke; Mark Danta; Stefan Mauss; Hans-Jürgen Stellbrink; Axel Baumgarten; Christoph Mayr; Raffaele Bruno; Cristina Tural; Gerd Klausen; Bonaventura Clotet; Uwe Naumann; Thomas Lutz; Michael Rausch; Knud Schewe; Bernhard Bienek; Georg Haerter; Tilman Sauerbruch; Jürgen K Rockstroh; Ulrich Spengler
Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.
The Journal of infectious diseases 2011;203(5):595-601.
2011: Felipe García; Núria Climent; Lambert Assoumou; Cristina Gil; Nuria González; José Alcamí; Agathe León; Joan Romeu; Judith Dalmau; Javier Martínez-Picado; Jeff Lifson; Brigitte Autran; Dominique Costagliola; Bonaventura Clotet; Josep M Gatell; Montserrat Plana; Teresa Gallart
A therapeutic dendritic cell-based vaccine for HIV-1 infection.
The Journal of infectious diseases 2011;203(4):473-8.
2011: Arkaitz Imaz; Josep M Llibre; Marta Mora; Gracia Mateo; Angela Camacho; José R Blanco; Adria Curran; José R Santos; Estrella Caballero; Isabel Bravo; Francisco Gayá; Pere Domingo; Antonio Rivero; Vicenç Falcó; Bonaventura Clotet; Esteban Ribera
Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
The Journal of antimicrobial chemotherapy 2011;66(2):358-62.
2011: Laura Papagno; Galit Alter; Lambert Assoumou; Robert L Murphy; Felipe Garcia; Bonaventura Clotet; Martin Larsen; Martine Braibant; Anne-Geneviève Marcelin; Dominique Costagliola; Marcus Altfeld; Christine Katlama; Brigitte Autran
Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine.
AIDS (London, England) 2011;25(1):27-36.
2011: Cristina Tural; Miguel Ángel von Wichmann; Ana Moreno Zamora; Núria Pérez Alvarez; Bonaventura Clotet; Juan González; Montserrat Laguno; José Moltó; Arelly Ornelas; Roger Paredes; Matilde Sánchez; Ricard Solà; Maria Jesús Téllez
Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Antiviral therapy 2011;16(6):833-41.
2011: Zoe Fox; Anders Karlsson; Jesper Kjaer; Gitte Kronborg; Jens D Lundgren; Andrew N Phillips; Bonaventura Clotet; Alessandro Cozzi-Lepri; Antonella d'Arminio Monforte
Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA.
Antiviral therapy 2011;16(5):781-5.
2011: Bernd Kupfer; Jens D Lundgren; Amanda Mocroft; Jacqueline Neuhaus; Lars Peters; Massimo Puoti; Jürgen Rockstroh; Vincent Soriano; Ellen Tedaldi; Bonaventura Clotet; Gregory Dore; Marina B Klein
Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study.
Antiviral therapy 2011;16(5):667-75.
2011: Francisco M Codoñer; Christian Pou; Alexander Thielen; Federico García; Rafael Delgado; David Dalmau; Lidia Ruiz; Bonaventura Clotet; Miguel Alvarez-Tejado; Roger Paredes
Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.
PloS one 2011;6(5):e19461.
2011: Ester Ballana; Eduardo Pauls; Bonaventura Clotet; Françoise Perron-Sierra; Gordon C Tucker; José A Esté
β5 integrin is the major contributor to the αVintegrin-mediated blockade of HIV-1 replication.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(1):464-70.
2011: José Moltó; Marta Valle; Cristina Miranda; Samandhy Cedeño; Eugenia Negredo; Manuel José Barbanoj; Bonaventura Clotet
Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
Antimicrobial agents and chemotherapy 2011;55(1):326-30.
2011: José Moltó; Marta Valle; David Back; Samandhy Cedeño; Victoria Watson; Neill Liptrott; Deirdre Egan; Cristina Miranda; Manuel J Barbanoj; Bonaventura Clotet
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
Antimicrobial agents and chemotherapy 2011;55(1):72-5.
2010: Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Huldrych F Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Update of the drug resistance mutations in HIV-1: December 2010.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2010;18(5):156-63.
2010: Anna Bonjoch; Beatriz Bayés; Joaquim Riba; Jordi Puig; Carla Estany; Núria Perez-Alvarez; Bonaventura Clotet; Eugènia Negredo
Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort.
Antiviral research 2010;88(3):347-54.
2010: Francisco M Codoñer; Christian Pou; Alexander Thielen; Federico García; Rafael Delgado; David Dalmau; José Ramon Santos; Maria José Buzón; Javier Martínez-Picado; Miguel Alvarez-Tejado; Bonaventura Clotet; Lidia Ruiz; Roger Paredes
Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
Antiviral research 2010;88(3):281-6.
2010: Anna Bonjoch; Marta Figueras; Carla Estany; Núria Perez-Alvarez; Joaquim Rosales; Luís del Rio; Silvana di Gregorio; Jordi Puig; Guadalupe Gómez; Bonaventura Clotet; Eugènia Negredo
High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.
AIDS (London, England) 2010;24(18):2827-33.
2010: Josep M Llibre; Antonio Antela; José Ramón Arribas; Pere Domingo; Josep M Gatell; José López Aldeguer; Fernando Lozano; Celia Miralles; José Moltó; Santiago Moreno; Enrique Ortega; Melcior Riera; Antonio Rivero; Concepción Villalonga; Bonaventura Clotet
[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy].
Enfermedades infecciosas y microbiología clínica 2010;28(9):615-20.
2010: José Moltó; Marta Valle; José Ramón Santos; Cristina Miranda; Samandhy Cedeño; Eugenia Negredo; Mercedes Yritia; Sebastián Videla; Bonaventura Clotet
Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir.
AIDS research and human retroviruses 2010;26(11):1191-6.
2010: Bonaventura Clotet; Nathan Clumeck; Christine Katlama; Steven Nijs; James Witek
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
The Journal of antimicrobial chemotherapy 2010;65(11):2450-4.
2010: Emmanuel González-Ortega; Maria-Pau Mena; Marc Permanyer; Ester Ballana; Bonaventura Clotet; José A Esté
ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.
Antimicrobial agents and chemotherapy 2010;54(10):4487-92.
2010: Echeverria Patricia; Pere Domingo; Mar Gutierrez; Mateo Gracia; Monse Fuster; José Molto; Jordi Puig; Nuria Perez-Alvarez; Bonaventura Clotet; Eugenia Negredo
Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients.
Current HIV research 2010;8(6):467-70.
2010: Sofia Pettersson; Violeta I Pérez-Nueno; Maria Pau Mena; Bonaventura Clotet; José A Esté; José I Borrell; Jordi Teixidó
Novel monocyclam derivatives as HIV entry inhibitors: Design, synthesis, anti-HIV evaluation, and their interaction with the CXCR4 co-receptor.
ChemMedChem 2010;5(8):1272-81.
2010: J Reekie; Amanda Mocroft; bruno ledergerber; Marek Beniowski; Bonaventura Clotet; J van Lunzen; Antonio Chiesi; Christian Pradier; L Machala; Jens D Lundgren
History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change.
HIV medicine 2010;11(7):469-78.
2010: José Moltó; José Sanz-Moreno; Marta Valle; Samandhy Cedeño; Jordi Bonal; Hanane Bouarich; Bonaventura Clotet
Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease.
Antimicrobial agents and chemotherapy 2010;54(7):3047-8.
2010: Eugenia Negredo; Joan Romeu; Benjamí Rodríguez-Santiago; Oscar Miró; Glòria Garrabou; Jordi Puig; Núria Pérez-Alvarez; Constanza Moren; Lidia Ruiz; Rocio Bellido; Cristina Miranda; Bonaventura Clotet
Mild improvement in mitochondrial function after a 3-year antiretroviral treatment interruption despite persistent impairment of mitochondrial DNA content.
Current HIV research 2010;8(5):379-85.
2010: M P Cañadas; L Darwich; Guillem Sirera; V Cirigliano; M Bofill; Bonaventura Clotet; S Videla
New molecular method for the detection of human papillomavirus type 16 integration.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2010;16(7):836-42.
2010: Jose Munoz-Moreno; Carmina R Fumaz; Anna Prats; Maria J Ferrer; Eugenia Negredo; Núria Pérez-Alvarez; José Moltó; Guadalupe Gómez; Maite Garolera; Bonaventura Clotet
Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
Journal of neurovirology 2010;16(3):208-18.
2010: Eugenia Negredo; Marta Massanella; Jordi Puig; Núria Pérez-Alvarez; José Miguel Gallego-Escuredo; Joan Villarroya; Francesc Villarroya; José Moltó; José Ramón Santos; Bonaventura Clotet; Julià Blanco
Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(9):1300-8.
2010: María-Paz Cañadas; Laila Darwich; Guillem Sirera; Margarita Bofill; Marta Piñol; Francesc Garcia-Cuyas; Mariona Llatjos; Patricia Corbasi; Bonaventura Clotet; Sebastián Videla
Human papillomavirus 16 integration and risk factors associated in anal samples of HIV-1 infected men.
Sexually transmitted diseases 2010;37(5):311-5.
2010: Marta Massanella; Eugenia Negredo; Núria Pérez-Alvarez; Jordi Puig; Raul Ruiz-Hernández; Margarita Bofill; Bonaventura Clotet; Julià Blanco
CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART.
AIDS (London, England) 2010;24(7):959-68.
2010: Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark E Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
Nature medicine 2010;16(4):460-5.
2010: Ester Ballana; Jordi Senserrich; Eduardo Pauls; Rosa Faner; Josep Maria Mercader; Frédéric Uyttebroeck; Eduard Palou; Maria Pau Mena; Eulalia Grau; Bonaventura Clotet; Lidia Ruiz; Amalio Telenti; Angela Ciuffi; José A Esté
ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(7):1022-32.
2010: Gregory J Dore; Vicente Soriano; Jürgen Rockstroh; Bernd Kupfer; Ellen Tedaldi; Lars Peters; Jacqueline Neuhaus; Massimo Puoti; Marina B Klein; Amanda Mocroft; Bonaventura Clotet; Jens D Lundgren
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.
AIDS (London, England) 2010;24(6):857-65.
2010: Josep M Llibre; Jonathan M Schapiro; Bonaventura Clotet
Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(6):872-81.
2010: Mercedes Armand-Ugón; Gemma Moncunill; Emmanuel Gonzalez; MariaPau Mena; Ester Ballana; Bonaventura Clotet; José A Esté
Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5.
The Journal of antimicrobial chemotherapy 2010;65(3):417-24.
2010: Roy T Steigbigel; David A Cooper; Hedy Teppler; Joseph J Eron; Jose M Gatell; Princy N Kumar; Jurgen K Rockstroh; Mauro Schechter; Christine Katlama; Martin Markowitz; Patrick Yeni; Mona R Loutfy; Adriano Lazzarin; Jeffrey Lennox; Bonaventura Clotet; Jing Zhao; Hong Wan; Rand R Rhodes; Kim M Strohmaier; Richard J Barnard; Robin D Isaacs; Bach-Yen Nguyen
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(4):605-12.
2010: Joan Romeu; Bonaventura Clotet
[HIV sexual transmission. Should we review the risk among individuals with long-term viral supression?].
Medicina clínica 2010;134(4):158-60.
2010: José Moltó; Elisabet Deig; Marta Valle; Josep Maria Llibre; Cristina Miranda; Samandhy Cedeño; Silvia Valero; Eugenia Negredo; Bonaventura Clotet
Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Therapeutic drug monitoring 2010;32(1):93-6.
2010: P Echeverría; Eugenia Negredo; G Carosi; J Gálvez; J L Gómez; A Ocampo; J Portilla; A Prieto; J C López; R Rubio; A Mariño; Enric Pedrol; Consuelo Viladés; A del Arco; A Moreno; I Bravo; R López-Blazquez; Núria Pérez-Alvarez; Bonaventura Clotet
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
Antiviral research 2010;85(2):403-8.
2010: Maria José Buzón; Judith Dalmau; Maria Carmen Puertas; Jordi Puig; Bonaventura Clotet; Javier Martinez-Picado
The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
AIDS (London, England) 2010;24(1):17-25.
2010: Andrew M Hill; Bonaventura Clotet; Margaret Johnson; Matthias Stoll; Nicholas Bellos; Erik Smets
Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
PharmacoEconomics 2010;28 Suppl 1():69-81.
2010: Ester Aparicio; Mariona Parera; Sandra Franco; Núria Pérez-Alvarez; Cristina Tural; Bonaventura Clotet; Miguel Angel Martínez
IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.
PloS one 2010;5(10):e13771.
2010: Christine Katlama; Bonaventura Clotet; Anthony Mills; Benoit Trottier; Jean-Michel Molina; Beatriz Grinsztejn; William Towner; Richard Haubrich; Steven Nijs; Johan Vingerhoets; Brian Woodfall; James Witek
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Antiviral therapy 2010;15(7):1045-52.
2010: Carolynne Schwarze-Zander; Markus Neibecker; Sabrina Othman; Cristina Tural; Bonaventura Clotet; Jason T Blackard; Bernd Kupfer; Guido Luechters; Raymond T Chung; Jürgen K Rockstroh; Ulrich Spengler
GB virus C coinfection in advanced HIV type-1 disease is associated with low CCR5 and CXCR4 surface expression on CD4(+) T-cells.
Antiviral therapy 2010;15(5):745-52.
2010: Victoria L Demetriou; David A M C van de Vijver; Ioanna Kousiappa; Claudia Balotta; Bonaventura Clotet; Zehava Grossman; Louise B Jørgensen; Snjezana Z Lepej; Itzchak Levy; Claus Nielsen; Dimitrios Paraskevis; Mario Poljak; Francois Roman; Lidia Ruiz; Jean-Claude Schmidt; Anne-Mieke Vandamme; Kristel Van Laethem; Jurgen Vercauteren; Leondios G Kostrikis
Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe.
PloS one 2010;5(6):e10976.
2010: Francesc Cunyat; Lidia Ruiz; Silvia Marfil; Teresa Puig; Margarita Bofill; Juliá Blanco; Bonaventura Clotet; Cecilia Cabrera
Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
Antiviral therapy 2010;15(3):431-6.
2010: Marta Massanella; Cristina Tural; Laura Papagno; Elisabet Garcia; Antoni Jou; Margarita Bofill; Brigitte Autran; Bonaventura Clotet; Julià Blanco
Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
Antiviral therapy 2010;15(3):333-42.
2010: José Moltó; Marta Valle; José Ramón Santos; Beatriz Mothe; Cristina Miranda; Samandhy Cedeño; Eugenia Negredo; Mercedes Yritia; Sebastián Videla; Manuel José Barbanoj; Bonaventura Clotet
Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Antiviral therapy 2010;15(2):219-25.
2010: Anne Aucher; Isabel Puigdomènech; Etienne Joly; Bonaventura Clotet; Denis Hudrisier; Julià Blanco
Could CD4 capture by CD8+ T cells play a role in HIV spreading?
Journal of biomedicine & biotechnology 2010;2010():907371.
2010: Roger Paredes; Bonaventura Clotet
Clinical management of HIV-1 resistance.
Antiviral research 2010;85(1):245-65.
2009: Josep M Llibre; José Ramón Santos; Bonaventura Clotet
[Etravirine: genetic barrier and resistance development].
Enfermedades infecciosas y microbiología clínica 2009;27 Suppl 2():32-9.
2009: Victoria A Johnson; Francoise Brun-Vezinet; Bonaventura Clotet; Huldrych F Gunthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Update of the drug resistance mutations in HIV-1: December 2009.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2009;17(5):138-45.
2009: María J Pérez-Elías; María Larrousse Morellon; Enrique Ortega; José Hernández Quero; Maribel Rodríguez-Torres; Bonaventura Clotet; Franco Felizarta; Felix Gutiérrez; Juan A Pineda; Garrett Nichols; Yu Lou; Mary Beth Wire
Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
Antimicrobial agents and chemotherapy 2009;53(12):5185-96.
2009: José R Santos; Josep M Llibre; Elena Ferrer; Pere Domingo; Arkaitz Imaz; José Moltó; Raquel Martin-Iguacel; Carme Caum; Daniel Podzamczer; Bonaventura Clotet
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
HIV clinical trials 2009;10(6):432-8.
2009: Beatriz Mothe; Iñaki Perez; Pere Domingo; Daniel Podzamczer; Esteban Ribera; Adrian Curran; Consuelo Viladés; Francesc Vidal; David Dalmau; Enric Pedrol; Eugenia Negredo; José Moltó; Roger Paredes; Núria Perez-Alvarez; Jose Maria Gatell; Bonaventura Clotet
HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain.
Current HIV research 2009;7(6):597-600.
2009: Carmina R Fumaz; Marian Gonzalez-Garcia; Xavier Borras; Maria José Ferrer; Jose Munoz-Moreno; Ruth Peña; Nuria Perez-Alvarez; Jordi Puig; Roger Paredes; Jordi Fernandez-Castro; Bonaventura Clotet
Increased peripheral proinflammatory cytokines in HIV-1-infected patients with prolonged viral suppression suffering from high psychological stress.
Journal of acquired immune deficiency syndromes (1999) 2009;52(3):427-8.
2009: Mariona Parera; Nuria Perez-Alvarez; Bonaventura Clotet; Miguel Angel Martínez
Epistasis among deleterious mutations in the HIV-1 protease.
Journal of molecular biology 2009;392(2):243-50.
2009: Eugenia Negredo; Oscar Miró; Benjamí Rodríguez-Santiago; Glòria Garrabou; Carla Estany; Angels Masabeu; Lluís Force; Pilar Barrufet; Josep Cucurull; Pere Domingo; Carlos Alonso-Villaverde; Anna Bonjoch; Constanza Morén; Núria Pérez-Alvarez; Bonaventura Clotet
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(6):892-900.
2009: Francisco Rodríguez Arrondo; Koldo Aguirrebengoa; Joseba Portu; Josefa Muñoz; M Asunción García; Josune Goikoetxea; Eduardo Martínez; José A Iribarren; Nuria Perez-Alvarez; Eugenia Negredo; Bonaventura Clotet
Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine.
Current HIV research 2009;7(5):526-32.
2009: Alessandro Cozzi-Lepri; Andrew N Phillips; Javier Martinez-Picado; Antonella d'Arminio Monforte; Christine Katlama; Ann-Brit Eg Hansen; Andrzej Horban; Johann Bruun; Bonaventura Clotet; Jens D Lundgren
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
The Journal of infectious diseases 2009;200(5):687-97.
2009: Maria Carmen Puertas; Maria Jose Buzón; Anna Artese; Stefano Alcaro; Luis Menendez-Arias; Carlo Federico Perno; Bonaventura Clotet; Francesca Ceccherini-Silberstein; Javier Martinez-Picado
Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.
Journal of virology 2009;83(15):7434-9.
2009: María Jesús Pérez-Elías; Jose María Gatell; Juan Flores; Jesús Santos; Francisco Vera-Médez; Bonaventura Clotet; Ana Moreno; Jose-Antonio Pérez-Molina; Belén Vendrell; Oscar Serrano
Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
HIV clinical trials 2009;10(4):269-75.
2009: Josep M Llibre; Vicenç Falco; Cristina Tural; Eugenia Negredo; Juan A Pineda; Jose Muñoz; Enrique Ortega; Sebastia Videla; Guillem Sirera; Esteban Martinez; Celia Miralles; Josean Iribarren; Maria J Galindo; Pere Domingo; Antonella d'Arminio Monforte; Jose M Miro; Bonaventura Clotet
The changing face of HIV/AIDS in treated patients.
Current HIV research 2009;7(4):365-77.
2009: Eva Heras; Josep M Llibre; Guillem Sirera; Jose L Mate; Vicente Boix; Celestino Rey-Joly; Bonaventura Clotet
Lymphogranuloma venerium proctitis in the setting of HIV: a case report and differential diagnosis.
AIDS patient care and STDs 2009;23(7):493-4.
2009: Imma Clotet-Codina; Berta Bosch; Jordi Senserrich; María Teresa Fernández-Figueras; Ruth Peña; Ester Ballana; Margarita Bofill; Bonaventura Clotet; José A Esté
HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection.
Antiviral research 2009;83(1):94-8.
2009: Esteban Martínez; José A Arranz; Daniel Podzamczer; Montserrat Loncá; José Sanz; Patricia Barragán; Esteban Ribera; Hernando Knobel; Victor Roca; Félix Gutiérrez; José L Blanco; Josep Mallolas; Josep M Llibre; Bonaventura Clotet; David Dalmau; Ferran Segura; José R Arribas; Jaime Cosín; Pilar Barrufet; Esperanza Casas; Elena Ferrer; Adrià Curran; Alicia González; Judit Pich; Ana Cruceta; Joan A Arnaiz; José M Miró; José M Gatell
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Journal of acquired immune deficiency syndromes (1999) 2009;51(3):290-7.
2009: Arantza Sanvisens; I Serra; Cristina Tural; Jordi Tor; Isabel Ojanguren; E Barluenga; Celestino Rey-Joly; Bonaventura Clotet; Roberto Muga
Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection.
Journal of viral hepatitis 2009;16(7):513-8.
2009: Robert L Murphy; Brigitte Autran; Christine Katlama; Gilles Brucker; Patrice Debre; Vincent Calvez; Bonaventura Clotet; Nathan Clumeck; Dominique Costagliola; Steven G Deeks; Lucy Dorrell; Jose Gatell; Ashley Haase; Michel Klein; Adriano Lazzarin; Andrew J McMichael; Laura Papagno; Timothy W Schacker; Simon Wain-Hobson; Bruce D Walker; Michael Youle
A step ahead on the HIV collaboratory.
Science (New York, N.Y.) 2009;324(5932):1264-5.
2009: Carmina R Fumaz; Jose Munoz-Moreno; María José Ferrer; Eugenia Negredo; Núria Pérez-Alvarez; Antoni Tarrats; Bonaventura Clotet
Low levels of adherence to antiretroviral therapy in HIV-1-infected women with menstrual disorders.
AIDS patient care and STDs 2009;23(6):463-8.
2009: Michael Saag; James Goodrich; Gerd Fätkenheuer; Bonaventura Clotet; Nathan Clumeck; John Sullivan; Mike Westby; Elna van der Ryst; Howard Mayer
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
The Journal of infectious diseases 2009;199(11):1638-47.
2009: José Ramón Santos; José Moltó; Josep M Llibre; Nuria Pérez; Cristina Miranda; Bonaventura Clotet
Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
HIV clinical trials 2009;10(3):129-34.
2009: Josep Mallolas; Daniel Podzamczer; Ana Milinkovic; Pere Domingo; Bonaventura Clotet; Esteve Ribera; Félix Gutiérrez; Hernando Knobel; Jaime Cosin; Elena Ferrer; José Alberto Arranz; Victor Roca; Francesc Vidal; Javier Murillas; Judit Pich; Enric Pedrol; Josep M Llibre; David Dalmau; Isabel García; Miquel Aranda; Ana Cruceta; Esteban Martínez; José L Blanco; Elisa de Lazzari; José M Gatell
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Journal of acquired immune deficiency syndromes (1999) 2009;51(1):29-36.
2009: José Moltó; Josep Maria Llibre; Esteban Ribera; Carlos Mínguez; Jesús Sánchez del Río; Enric Pedrol; Gabriel Vallecillo; Samandhy Cedeño; Marta Valle; Cristina Miranda; Eugenia Negredo; Bonaventura Clotet
Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
The Journal of antimicrobial chemotherapy 2009;63(5):992-7.
2009: Alain Pruvost; Eugènia Negredo; Frédéric Théodoro; Jordi Puig; Mikaël Levi; Rafaela Ayen; Jacques Grassi; Bonaventura Clotet
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Antimicrobial agents and chemotherapy 2009;53(5):1937-43.
2009: Jose Munoz-Moreno; Carmina R Fumaz; Maria J Ferrer; Marian González-García; José Moltó; Eugenia Negredo; Bonaventura Clotet
Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
AIDS reviews 2009;11(2):103-9.
2009: Eugenia Negredo; Jordi Puig; David Aldea; Manuel Medina; Carla Estany; Núria Pérez-Alvarez; Carmina Rodríguez-Fumaz; Jose Munoz-Moreno; Carmen Higueras; Vicente Gonzalez-Mestre; Bonaventura Clotet
Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy.
AIDS research and human retroviruses 2009;25(4):451-5.
2009: Gerard Minuesa; Christopher Volk; Míriam Molina-Arcas; Valentin Gorboulev; Itziar Erkizia; Petra Arndt; Bonaventura Clotet; Marçal Pastor-Anglada; Hermann Koepsell; Javier Martinez-Picado
Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.
The Journal of pharmacology and experimental therapeutics 2009;329(1):252-61.
2009: Nuria Izquierdo-Useros; Mar Naranjo-Gómez; Jacob Archer; Steven C Hatch; Itziar Erkizia; Julià Blanco; Francesc E Borras; Maria Carmen Puertas; John H Connor; Maria Teresa Fernández-Figueras; Landon Moore; Bonaventura Clotet; Suryaram Gummuluru; Javier Martinez-Picado
Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway.
Blood 2009;113(12):2732-41.
2009: Marianne Harris; Hélène Côté; Claudia Ochoa; Clotilde Allavena; Eugenia Negredo; Anona Thorne; Pedro Cahn; Carlos Zala; Francois Raffi; Bonaventura Clotet; Joel Singer; Julio Montaner
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2009;50(3):335-7.
2009: Cristina Tural; Jordi Tor; Arantza Sanvisens; Núria Pérez-Alvarez; Elisenda Martínez; Isabel Ojanguren; Javier García-Samaniego; Juergen Rockstroh; Eva Barluenga; Roberto Muga; Ramon Planas; Guillem Sirera; Celestino Rey-Joly; Bonaventura Clotet
Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2009;7(3):339-45.
2009: Laila Darwich; Gemma Coma; Ruth Peña; Rocio Bellido; Ester J J Blanco; José A Este; Francesc E Borras; Bonaventura Clotet; Lidia Ruiz; Antoni Rosell; Felipe Andreo; R Michael E Parkhouse; Margarita Bofill
Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18.
Immunology 2009;126(3):386-93.
2009: Ester Ballana; Eduardo Pauls; Jordi Senserrich; Bonaventura Clotet; Françoise Perron-Sierra; Gordon C Tucker; José A Esté
Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages.
Blood 2009;113(6):1278-86.
2009: Sebastian Videla; Laila Darwich; Maria Paz Cañadas; Roger Paredes; Antoni Tarrats; Eva Castella; Mariona Llatjos; Margarita Bofill; Bonaventura Clotet; Guillem Sirera
Epidemiological data of different human papillomavirus genotypes in cervical specimens of HIV-1-infected women without history of cervical pathology.
Journal of acquired immune deficiency syndromes (1999) 2009;50(2):168-75.
2009: Judith Dalmau; Maria Carmen Puertas; Marta Azuara; Ana Mariño; Nicole Frahm; Beatriz Mothe; Nuria Izquierdo-Useros; Maria José Buzón; Roger Paredes; Lourdes Matas; Todd M Allen; Christian Brander; Carlos Rodrigo; Bonaventura Clotet; Javier Martinez-Picado
Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(2):229-38.
2009: Eduardo Pauls; Ester Ballana; Gemma Moncunill; Margarida Bofill; Bonaventura Clotet; Cristina Ramo-Tello; José A Esté
Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4.
AIDS (London, England) 2009;23(2):266-8.
2009: Marta Massanella; Isabel Puigdomènech; Cecilia Cabrera; Maria Teresa Fernandez Figueras; Anne Aucher; Gerald Gaibelet; Denis Hudrisier; Elisabet García; Margarita Bofill; Bonaventura Clotet; Julià Blanco
Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells.
AIDS (London, England) 2009;23(2):183-8.
2009: Isabel Puigdomènech; Marta Massanella; Cecilia Cabrera; Bonaventura Clotet; Julià Blanco
On the steps of cell-to-cell HIV transmission between CD4 T cells.
Retrovirology 2009;6():89.
2009: Federico Pulido; Ignacio Pérez-Valero; Rafael Delgado; Alberto Arranz; Juan Pasquau; Joaquín Portilla; Rafael Rubio; Juan González-García; Pilar Miralles; Maria J Pérez-Elías; Antonio Ocampo; Asunción Hernando; Vicente Estrada; Bonaventura Clotet; Daniel Podzamczer; José R Arribas
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
Antiviral therapy 2009;14(2):195-201.
2009: Robert Horne; Colin Kovacs; Christine Katlama; Bonaventura Clotet; Carmina R Fumaz; Mike Youle; Ranjababu Kulasegaram; Martin Fisher; Calvin Cohen; Jihad Slim; Peter Shalit; Vanessa Cooper; Christos M Tsoukas
Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?
AIDS research and therapy 2009;6():2.
2008: Laila Darwich; Cecilia Cabrera; Joan Romeu; Javier Martinez-Picado; José A Esté; Cristina Tural; Rocio Bellido; Bonaventura Clotet; Ana Angulo; Lidia Ruiz; Margarita Bofill
The magnitude of interferon-gamma responses to human cytomegalovirus is predictive for HIV-1 disease progression.
Journal of acquired immune deficiency syndromes (1999) 2008;49(5):507-12.
2008: José Moltó; Bonaventura Clotet
[Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].
Enfermedades infecciosas y microbiología clínica 2008;26 Suppl 16():24-6.
2008: Ellen M Tedaldi; Lars Peters; Jacquie Neuhaus; Massimo Puoti; Jürgen Rockstroh; Marina B Klein; Gregory J Dore; Amanda Mocroft; Vincent Soriano; Bonaventura Clotet; Jens D Lundgren
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47(11):1468-75.
2008: Bonaventura Clotet; Amedeo Capetti; Luis E Soto-Ramirez; Jose M Gatell; Lucy Rowell; Miklos Salgo; Jonathan M Schapiro
A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study.
The Journal of antimicrobial chemotherapy 2008;62(6):1374-8.
2008: José Moltó; José R Santos; Nuria Pérez-Alvarez; Samandhy Cedeño; Cristina Miranda; Saye Khoo; Laura Else; Josep Maria Llibre; Marta Valle; Bonaventura Clotet
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2008;52(11):3928-32.
2008: J M Llibre; J R Santos; T Puig; José Moltó; Lidia Ruiz; Roger Paredes; Bonaventura Clotet
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
The Journal of antimicrobial chemotherapy 2008;62(5):909-13.
2008: Berta Bosch; Boyan Grigorov; Jordi Senserrich; Bonaventura Clotet; Jean-Luc Darlix; Delphine Muriaux; José A Este
A clathrin-dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell-T cell transmission.
Antiviral research 2008;80(2):185-93.
2008: Alessandro Cozzi-Lepri; Andrew N Phillips; Bonaventura Clotet; Amanda Mocroft; Lidia Ruiz; Ole Kirk; Adriano Lazzarin; Alicja Wiercinska-Drapalo; Anders Karlsson; Jens D Lundgren
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
AIDS (London, England) 2008;22(16):2187-98.
2008: Julian H Elliott; Lutgarde Lynen; Alexandra Calmy; Andrea De Luca; Robert W Shafer; Maria Zolfo; Bonaventura Clotet; Sarah Huffam; Charles A B Boucher; David A Cooper; Jonathan M Schapiro
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
AIDS (London, England) 2008;22(16):2053-67.
2008: Roy M Gulick; Jacob Lalezari; James Goodrich; Nathan Clumeck; Edwin DeJesus; Andrzej Horban; Jeffrey Nadler; Bonaventura Clotet; Anders Karlsson; Michael Wohlfeiler; John B Montana; Mary McHale; John Sullivan; Caroline Ridgway; Steve Felstead; Michael W Dunne; Elna van der Ryst; Howard Mayer
Maraviroc for previously treated patients with R5 HIV-1 infection.
The New England journal of medicine 2008;359(14):1429-41.
2008: Bonaventura Clotet
[Position of darunavir in antiretroviral therapy].
Enfermedades infecciosas y microbiología clínica 2008;26 Suppl 10():61-2.
2008: José Moltó; Marta Valle; Bonaventura Clotet
[Pharmacological interactions with darunavir].
Enfermedades infecciosas y microbiología clínica 2008;26 Suppl 10():43-50.
2008: Bonaventura Clotet
[Introduction. Darunavir].
Enfermedades infecciosas y microbiología clínica 2008;26 Suppl 10():1-2.
2008: Jose Munoz-Moreno; Carmina R Fumaz; Maria J Ferrer; Anna Prats; Eugenia Negredo; Maite Garolera; Núria Pérez-Alvarez; José Moltó; Guadalupe Gómez; Bonaventura Clotet
Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients.
AIDS research and human retroviruses 2008;24(10):1301-7.
2008: Sofia Pettersson; Violeta I Pérez-Nueno; Laia Ros-Blanco; Raimon Puig de La Bellacasa; María Obdulia Rabal; Xavier Batllori; Bonaventura Clotet; Imma Clotet-Codina; Mercedes Armand-Ugón; José A Esté; José I Borrell; Jordi Teixidó
Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors.
ChemMedChem 2008;3(10):1549-57.
2008: José Moltó; Marta Valle; Cristina Miranda; Samandhy Cedeño; José Miranda; José Ramón Santos; Eugenia Negredo; Josep Vilaró; Joan Costa; Bonaventura Clotet
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
The Journal of antimicrobial chemotherapy 2008;62(4):784-92.
2008: Martin S Hirsch; Huldrych F Günthard; Jonathan M Schapiro; Françoise Brun-Vézinet; Bonaventura Clotet; Scott M Hammer; Victoria A Johnson; Daniel R Kuritzkes; John W Mellors; Deenan Pillay; Patrick G Yeni; Donna M Jacobsen; Douglas D Richman
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2008;16(3):266-85.
2008: Josep M Llibre; A Bonjoch; J Iribarren; María José Galindo; Eugenia Negredo; Pere Domingo; N Pérez-Alvarez; J Martinez-Picado; J Schapiro; Bonaventura Clotet
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
HIV medicine 2008;9(7):508-13.
2008: David A Cooper; Roy T Steigbigel; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey Lennox; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Hedy Teppler; Bach-Yen Nguyen
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):355-65.
2008: Roy T Steigbigel; David A Cooper; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey Lennox; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Bach-Yen Nguyen; Hedy Teppler
Raltegravir with optimized background therapy for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):339-54.
2008: Martin S Hirsch; Huldrych F Günthard; Jonathan M Schapiro; Françoise Brun-Vézinet; Bonaventura Clotet; Scott M Hammer; Victoria A Johnson; Daniel R Kuritzkes; John W Mellors; Deenan Pillay; Patrick G Yeni; Donna M Jacobsen; Douglas D Richman
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47(2):266-85.
2008: Brigitte Autran; Robert L Murphy; Dominique Costagliola; Roland Tubiana; Bonaventura Clotet; Jose Gatell; Schlomo Staszewski; Norma Wincker; Lambert Assoumou; Raphaelle El Habib; Vincent Calvez; Bruce Walker; Christine Katlama
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
AIDS (London, England) 2008;22(11):1313-22.
2008: Wendy P Bannister; Alessandro Cozzi-Lepri; Bonaventura Clotet; Amanda Mocroft; Jesper Kjaer; Peter Reiss; Viktor von Wyl; Adriano Lazzarin; Christine Katlama; Andrew N Phillips; Lidia Ruiz; Jens D Lundgren
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
Journal of acquired immune deficiency syndromes (1999) 2008;48(3):324-33.
2008: Laila Darwich; Anna Esteve; Lidia Ruiz; Roger Paredes; Rocio Bellido; Cecilia Cabrera; Joan Romeu; Margarita Bofill; Bonaventura Clotet; Javier Martinez-Picado
Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
AIDS research and human retroviruses 2008;24(5):725-32.
2008: Victoria A Johnson; Françoise Brun Vezinet; Bonaventura Clotet; Huldrych F Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Update of the drug resistance mutations in HIV-1: Spring 2008.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2008;16(1):62-8.
2008: Gemma Moncunill; Mercedes Armand-Ugón; Imma Clotet-Codina; Eduardo Pauls; Ester Ballana; Anuska Llano; Barbara Romagnoli; Jan W Vrijbloed; Frank O Gombert; Bonaventura Clotet; Steven DeMarco; José A Esté
Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.
Molecular pharmacology 2008;73(4):1264-73.
2008: Brian Angus; Fiona Lampe; Guiseppe Tambussi; Claudine Duvivier; Christine Katlama; Mike Youle; Ian Williams; Bonaventura Clotet; Martin Fisher; Frank A Post; Abdul Babiker; Andrew Phillips
TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.
AIDS (London, England) 2008;22(6):737-40.
2008: Jordi Senserrich; Eduardo Pauls; Mercedes Armand-Ugón; Imma Clotet-Codina; Gemma Moncunill; Bonaventura Clotet; José A Esté
HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region.
Virology 2008;372(2):421-9.
2008: Eugenia Negredo; Isabel Puigdomènech; Silvia Marfil; Jordi Puig; Núria Pérez-Alvarez; Lidia Ruiz; Celestino Rey-Joly; Bonaventura Clotet; Julià Blanco
Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.
The Journal of antimicrobial chemotherapy 2008;61(2):400-4.
2008: Gerard Minuesa; Sergi Purcet; Itziar Erkizia; Míriam Molina-Arcas; Margarita Bofill; Nuria Izquierdo-Useros; F Javier Casado; Bonaventura Clotet; Marçal Pastor-Anglada; Javier Martinez-Picado
Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells.
The Journal of pharmacology and experimental therapeutics 2008;324(2):558-67.
2008: Sandra Franco; Bonaventura Clotet; Miguel Angel Martínez
A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
Virus research 2008;131(2):260-70.
2008: Wendy P Bannister; Lidia Ruiz; Alessandro Cozzi-Lepri; Amanda Mocroft; Ole Kirk; Schlomo Staszewski; Clive Loveday; Anders Karlsson; Antonella d'Arminio Monforte; Bonaventura Clotet; Jens D Lundgren
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
AIDS (London, England) 2008;22(3):367-76.
2008: Thomas Kuntzen; Cristina Tural; Bin Li; Georg Feldmann; Bernd Kupfer; Hans Dieter Nischalke; Bonaventura Clotet; Tilman Sauerbruch; Jürgen K Rockstroh; Ulrich Spengler
Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART.
AIDS (London, England) 2008;22(2):203-10.
2008: Gemma Moncunill; Mercedes Armand-Ugón; Eduardo Pauls; Bonaventura Clotet; José A Esté
HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
AIDS (London, England) 2008;22(1):23-31.
2008: Cristina Tural; Josep Antón Galeras; Ramon Planas; Susanna Coll; Guillem Sirera; Dolors Giménez; Anna Salas; Celestino Rey-Joly; Isabel Cirera; Carmen Márquez; Jordi Tor; Sebastián Videla; Montserrat García-Retortillo; Bonaventura Clotet; Ricard Solà
Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
Antiviral therapy 2008;13(8):1047-55.
2008: Laila Darwich; Anna Esteve; Lidia Ruiz; Rocio Bellido; Bonaventura Clotet; Javier Martinez-Picado
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Antiviral therapy 2008;13(7):945-51.
2008: Maria José Buzón; Silvia Marfil; Maria C Puertas; Elisabet Garcia; Bonaventura Clotet; Lidia Ruiz; Julìa Blanco; Javier Martinez-Picado; Cecilia Cabrera
Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
Antiviral therapy 2008;13(7):881-93.
2008: Guillem Sirera; Sebastià Videla; Joan Romeu; Maripaz Cañadas; Maria-Teresa Fernández; Susana Balo; Beatriz Cirauqui; Laila Darwich; Celestino Rey-Joly; Bonaventura Clotet
Fatal fast-evolution of nasopharyngeal squamous cell carcinoma in an HIV patient with EBV and HPV (-16 AND -33) in blood serum.
The open AIDS journal 2008;2():1-2.
2008: José Moltó; Manuel José Barbanoj; Cristina Miranda; Asunción Blanco; José Ramón Santos; Eugenia Negredo; Joan Costa; Pere Domingo; Bonaventura Clotet; Marta Valle
Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.
Clinical pharmacokinetics 2008;47(10):681-92.
2008: Koen Deforche; Alessandro Cozzi-Lepri; Kristof Theys; Bonaventura Clotet; Ricardo Camacho; Jesper Kjaer; Kristel Van Laethem; Andrew Phillips; Yves Moreau; Jens D Lundgren; Anne-Mieke Vandamme
Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
Antiviral therapy 2008;13(3):399-407.
2008: Eugènia Negredo; Glòria Garrabou; Jordi Puig; Sònia Lòpez; Constanza Morén; Rocio Bellido; Rafaela Ayen; Francesc Cardellach; Oscar Miró; Bonaventura Clotet
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
Antiviral therapy 2008;13(2):231-40.
2008: Isabel Puigdomènech; Marta Massanella; Nuria Izquierdo-Useros; Raul Ruiz-Hernandez; Marta Curriu; Margarita Bofill; Javier Martinez-Picado; Manel Juan; Bonaventura Clotet; Julià Blanco
HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4.
Retrovirology 2008;5():32.
2008: Amanda Mocroft; Andrzej Horban; Bonaventura Clotet; Antonella d'Arminio Monforte; J R Bogner; P Aldins; T Staub; Francisco Antunes; Christine Katlama; Jens D Lundgren
Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999.
HIV medicine 2008;9(1):41-6.
2008: Milos Opravil; Joseph Sasadeusz; David A Cooper; Jürgen K Rockstroh; Nathan Clumeck; Bonaventura Clotet; Julio Montaner; Francesca J Torriani; Jean DePamphilis; Douglas T Dieterich
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
Journal of acquired immune deficiency syndromes (1999) 2008;47(1):36-49.
2008: Bonaventura Clotet
Once-daily dosing of nevirapine in HAART.
The Journal of antimicrobial chemotherapy 2008;61(1):13-6.
2008: Josep M Llibre; Pere Domingo; Miguel A del Pozo; Celia Miralles; María José Galindo; Isabel Viciana; Santiago Moreno; Jonathan M Schapiro; Bonaventura Clotet
Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
The Journal of antimicrobial chemotherapy 2008;61(1):206-9.
2008: Guillem Sirera; Sebastián Videla; Raquel López-Blázquez; Mariona Llatjos; Antoni Tarrats; Eva Castellà; Nuria Grane; Cristina Tural; Celestino Rey-Joly; Bonaventura Clotet
Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3.
The Journal of antimicrobial chemotherapy 2008;61(1):191-4.
2007: Cristina Tural; Ramon Planas; Guillermo Sirera; Bonaventura Clotet
Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers.
Current opinion in HIV and AIDS 2007;2(6):496-502.
2007: Francesca Ceccherini-Silberstein; Alessandro Cozzi-Lepri; Lidia Ruiz; Amanda Mocroft; Andrew N Phillips; Christian Holkmann Olsen; José M Gatell; Huldrych F Gunthard; Peter Reiss; Carlo Federico Perno; Bonaventura Clotet; Jens D Lundgren
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients.
The Journal of infectious diseases 2007;196(8):1180-90.
2007: Jose Munoz-Moreno; Carmina R Fumaz; Maria José Ferrer; Albert Tuldrà; Tatiana Rovira; Carme Viladrich; Ramon Bayés; David Burger; Eugenia Negredo; Bonaventura Clotet
Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study.
AIDS research and human retroviruses 2007;23(10):1166-75.
2007: José Moltó; José Ramón Santos; Marta Valle; Cristina Miranda; José Miranda; Asunción Blanco; Eugenia Negredo; Bonaventura Clotet
Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Therapeutic drug monitoring 2007;29(5):648-51.
2007: Zoe Fox; Anna Maria Geretti; Jesper Kjaer; Ulrik B Dragsted; Andrew N Phillips; Jan Gerstoft; Schlomo Staszewski; Bonaventura Clotet; Viktor von Wyl; Jens D Lundgren
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
AIDS (London, England) 2007;21(15):2033-42.
2007: Cristina Tural; Ricard Solà; R Rubio; M Santín; Ramon Planas; C Quereda; Juan Berenguer; M Montes-Ramírez; Bonaventura Clotet
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
Journal of viral hepatitis 2007;14(10):704-13.
2007: Jacob Nattermann; Martin Vogel; Thomas Berg; Mark Danta; Baumgarten Axel; Christoph Mayr; RAFFAELE BRUNO; Cristina Tural; Gerd Klausen; Bonaventura Clotet; Thomas Lutz; Frank Grünhage; Michael Rausch; Hans Dieter Nischalke; Knud Schewe; Bernhard Bienek; Georg Haerter; Tilman Sauerbruch; Jürgen K Rockstroh; Ulrich Spengler
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
Hepatology (Baltimore, Md.) 2007;46(4):1016-25.
2007: Mireia Gimenez-Barcons; Bonaventura Clotet; Miguel Angel Martinez
Endoribonuclease-prepared short interfering RNAs induce effective and specific inhibition of human immunodeficiency virus type 1 replication.
Journal of virology 2007;81(19):10680-6.
2007: Mark A Wainberg; Bonaventura Clotet
Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review.
AIDS patient care and STDs 2007;21(9):609-20.
2007: Guillem Sirera; Sebastián Videla; Raquel López-Blázquez; Mariona Llatjos; Antoni Tarrats; Eva Castellà; Nuria Grane; Carmen Alcalde; Cristina Tural; Celestino Rey-Joly; Bonaventura Clotet
Evolution of cervical cytologic changes among HIV-infected women with normal cytology in the HAART era.
AIDS research and human retroviruses 2007;23(8):965-71.
2007: Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Huldrych Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Update of the drug resistance mutations in HIV-1: 2007.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2007;15(4):119-25.
2007: Jacques Reynes; Keikawus Arastéh; Bonaventura Clotet; Calvin Cohen; David A Cooper; Jean-François Delfraissy; Joseph J Eron; Keith Henry; Christine Katlama; Daniel R Kuritzkes; Jacob P Lalezari; Joep Lange; Adriano Lazzarin; Julio S G Montaner; Mark Nelson; Mary O' Hearn; Hans-Jürgen Stellbrink; Benoit Trottier; Sharon L Walmsley; Neil E Buss; Ralph DeMasi; Jain Chung; Lucille Donatacci; Denise Guimaraes; Lucy Rowell; Adeline Valentine; Martin Wilkinson; Miklos Salgo
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
AIDS patient care and STDs 2007;21(8):533-43.
2007: Bonaventura Clotet; Eugenia Negredo; Pierre Marie Girard; Mike Youle; Dietmar Neubacher
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
Journal of acquired immune deficiency syndromes (1999) 2007;45(4):479-81.
2007: José Moltó; José Ramón Santos; Eugenia Negredo; Cristina Miranda; Sebastián Videla; Bonaventura Clotet
Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
The Journal of antimicrobial chemotherapy 2007;60(2):436-9.
2007: Bonaventura Clotet
CCR5 inhibitors: promising yet challenging.
The Journal of infectious diseases 2007;196(2):178-80.
2007: Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christine Katlama; Arend Moll; William Towner; Benoit Trottier; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Benny Baeten; Greet Beets; Rekha Sinha; Brian Woodfall
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet 2007;370(9581):39-48.
2007: Anita Rachlis; Bonaventura Clotet; John Baxter; Robert Murphy; Eric Lefebvre
Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
HIV clinical trials 2007;8(4):213-20.
2007: Nuria Izquierdo-Useros; Julià Blanco; Itziar Erkizia; Maria Teresa Fernández-Figueras; Francesc E Borras; Mar Naranjo-Gómez; Margarita Bofill; Lidia Ruiz; Bonaventura Clotet; Javier Martinez-Picado
Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission.
Journal of virology 2007;81(14):7559-70.
2007: Guillermo Robert de Arquer; Ruth Peña; Cecilia Cabrera; Gemma Coma; Raul Ruiz-Hernandez; Rosa Guerola; Bonaventura Clotet; Lidia Ruiz; José A Esté; M Luz Calle; Margarita Bofill
Skewed expression and up-regulation of the IL-12 and IL-18 receptors in resting and activated CD4 T cells from HIV-1-infected patients.
Journal of leukocyte biology 2007;82(1):72-8.
2007: Mark R Nelson; Christine Katlama; Julio S G Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS (London, England) 2007;21(10):1273-81.
2007: José Moltó; Asunción Blanco; Cristina Miranda; José Miranda; Jordi Puig; Marta Valle; Meritxell DelaVarga; Carmina R Fumaz; Manel J Barbanoj; Bonaventura Clotet
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice.
British journal of clinical pharmacology 2007;63(6):715-21.
2007: Cristina Villena; Julia G Prado; Maria Carmen Puertas; Miguel Angel Martínez; Bonaventura Clotet; Lidia Ruiz; Neil Parkin; Luis Menéndez-Arias; Javier Martinez-Picado
Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.
Journal of virology 2007;81(9):4713-21.
2007: Bonaventura Clotet; Nicholas Bellos; Jean-Michel Molina; David Cooper; Jean-Christophe Goffard; Adriano Lazzarin; Andrej Wöhrmann; Christine Katlama; Timothy Wilkin; Richard Haubrich; Calvin Cohen; Charles Farthing; Dushyantha Jayaweera; Martin Markowitz; Peter Ruane; Sabrina Spinosa-Guzman; Eric Lefebvre
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Lancet 2007;369(9568):1169-78.
2007: Sandra Franco; Mariona Parera; Ester Aparicio; Bonaventura Clotet; Miguel Angel Martinez
Genetic and catalytic efficiency structure of an HCV protease quasispecies.
Hepatology (Baltimore, Md.) 2007;45(4):899-910.
2007: Alessandro Cozzi-Lepri; Andrew N Phillips; Lidia Ruiz; Bonaventura Clotet; Clive Loveday; Jesper Kjaer; Helene Mens; Nathan Clumeck; Ludmila Viksna; Francisco Antunes; Ladislav Machala; Jens D Lundgren
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
AIDS (London, England) 2007;21(6):721-32.
2007: Eugenia Negredo; Eva Martínez; Denise Cinquegrana; Carla Estany; Bonaventura Clotet
Therapeutic management of bone demineralization in the HIV-infected population.
AIDS (London, England) 2007;21(6):657-63.
2007: Bonaventura Clotet; Roger Paredes
Clinical approach to drug resistance interpretation: expert advice.
Current opinion in HIV and AIDS 2007;2(2):145-9.
2007: Guerau Fernàndez; Bonaventura Clotet; Miguel Angel Martínez
Fitness landscape of human immunodeficiency virus type 1 protease quasispecies.
Journal of virology 2007;81(5):2485-96.
2007: Mariona Parera; Guerau Fernàndez; Bonaventura Clotet; Miguel Angel Martínez
HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions.
Molecular biology and evolution 2007;24(2):382-7.
2007: Sandra Franco; Cristina Tural; Bonaventura Clotet; Miguel Angel Martínez
Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1.
Virus research 2007;123(2):161-9.
2007: Lidia Ruiz; Roger Paredes; Guadalupe Gómez; Joan Romeu; Pere Domingo; Núria Pérez-Alvarez; Giuseppe Tambussi; Josep M Llibre; Javier Martínez-Picado; Francesc Vidal; Carmina R Fumaz; Bonaventura Clotet
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
AIDS (London, England) 2007;21(2):169-78.
2007: José Moltó; Marta Valle; Asunción Blanco; Eugenia Negredo; Meritxell DelaVarga; Cristina Miranda; José Miranda; Pere Domingo; Josep Vilaró; Cristina Tural; Joan Costa; Manel J Barbanoj; Bonaventura Clotet
Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.
Clinical pharmacokinetics 2007;46(1):85-92.
2007: Eduardo Pauls; Jordi Senserrich; Margarita Bofill; Bonaventura Clotet; José A Esté
Induction of interleukins IL-6 and IL-8 by siRNA.
Clinical and experimental immunology 2007;147(1):189-96.
2007: Carmina R Fumaz; Jose Munoz-Moreno; Angel Luis Ballesteros; Roger Paredes; Maria José Ferrer; Anna Salas; Daniel Fuster; E Masmitjà; Núria Pérez-Alvarez; Guadalupe Gómez; Cristina Tural; Bonaventura Clotet
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
AIDS care 2007;19(1):138-45.
2006: Eugenia Negredo; Carmen Higueras; Xavier Adell; Juan Carlos Martinez; Eva Martinez; Jordi Puig; Carmina R Fumaz; Jose Munoz-Moreno; Nuria Perez-Alvarez; Sebastián Videla; Carla Estany; Denise Cinquegrana; Vicente Gonzalez-Mestre; Bonaventura Clotet
Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances.
AIDS patient care and STDs 2006;20(12):829-37.
2006: Eugenia Negredo; José Moltó; Jordi Puig; Denise Cinquegrana; Anna Bonjoch; Núria Pérez-Alvarez; Raquel López-Blázquez; Asunción Blanco; Bonaventura Clotet; Celestino Rey-Joly
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
AIDS (London, England) 2006;20(17):2159-64.
2006: José Moltó; Asunción Blanco; Cristina Miranda; José Miranda; Jordi Puig; Marta Valle; Meritxell DelaVarga; Carmina R Fumaz; Manel J Barbanoj; Bonaventura Clotet
Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.
British journal of clinical pharmacology 2006;62(5):560-6.
2006: Cecilia Cabrera; Silvia Marfil; Elisabet García; Javier Martinez-Picado; Anna Bonjoch; Margarita Bofill; Santiago Moreno; Esteban Ribera; Pere Domingo; Bonaventura Clotet; Lidia Ruiz
Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.
AIDS (London, England) 2006;20(16):2075-80.
2006: Anna Bonjoch; Eugenia Negredo; Jordi Puig; Itziar Erkizia; Teresa Puig; Cecilia Cabrera; Lidia Ruiz; Bonaventura Clotet
Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.
AIDS (London, England) 2006;20(14):1896-8.
2006: Margarita Bofill; Javier Martinez-Picado; Raul Ruiz-Hernandez; Cecilia Cabrera; Silvia Marfil; Itziar Erkizia; Rocio Bellido; Joan Romeu; Bonaventura Clotet; Lidia Ruiz
Naive CD4(+) T cells and recent thymic emigrant levels in treated individuals with HIV: clinical relevance.
AIDS research and human retroviruses 2006;22(9):893-6.
2006: Gemma Coma; Ruth Peña; Julià Blanco; A Rosell; Francesc E Borras; José A Esté; Bonaventura Clotet; Lidia Ruiz; R Michael E Parkhouse; Margarita Bofill
Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10.
Clinical and experimental immunology 2006;145(3):535-44.
2006: Eduardo Pauls; Jordi Senserrich; Bonaventura Clotet; José A Esté
Inhibition of HIV-1 replication by RNA interference of p53 expression.
Journal of leukocyte biology 2006;80(3):659-67.
2006: Charles B Hicks; Pedro Cahn; David A Cooper; Sharon L Walmsley; Christine Katlama; Bonaventura Clotet; Adriano Lazzarin; Margaret A Johnson; Dietmar Neubacher; Douglas Mayers; Hernan Valdez
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Lancet 2006;368(9534):466-75.
2006: Victoria A Johnson; Françoise Brun Vezinet; Bonaventura Clotet; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Update of the drug resistance mutations in HIV-1: Fall 2006.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2006;14(3):125-30.
2006: Eugenia Negredo; Anna Bonjoch; Bonaventura Clotet
Benefits and concerns of simplification strategies in HIV-infected patients.
The Journal of antimicrobial chemotherapy 2006;58(2):235-42.
2006: Juan Carlos López; Santiago Moreno; Fernando Jiménez-Oñate; Bonaventura Clotet; Rafael Rubio; Jose Hernández-Quero
A cohort study of the food effect on virological failure and treatment discontinuation in patients on HAART containing didanosine enteric-coated capsules (FOODDIe Study).
HIV clinical trials 2006;7(4):155-62.
2006: Mónica Gumá; Cecilia Cabrera; Itziar Erkizia; Margarita Bofill; Bonaventura Clotet; Lidia Ruiz; Miguel López-Botet
Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients.
The Journal of infectious diseases 2006;194(1):38-41.
2006: Guillem Sirera; Sebastián Videla; Marta Piñol; Mari P Cañadas; Mariona Llatjos; Angel Luis Ballesteros; Francisco García-Cuyás; Eva Castellá; Rosa Guerola; Cristina Tural; Celestino Rey-Joly; Bonaventura Clotet
High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men.
AIDS (London, England) 2006;20(8):1201-4.
2006: Ricard Solà; Josep Antón Galeras; Silvia Montoliu; Cristina Tural; Lluís Force; Sandra Torra; Santiago Montull; Eduardo Rodríguez De Castro; Susanna Coll; Daniel Fuster; Pilar Barrufet; Guillem Sirera; María D Giménez; Bonaventura Clotet; Ramon Planas
Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.
AIDS research and human retroviruses 2006;22(5):393-400.
2006: Guerau Fernàndez; Anuska Llano; Maria de la Cruz Dominguez-Punaro; Bonaventura Clotet; José A Esté; Miguel Angel Martínez
Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.
The Journal of general virology 2006;87(Pt 5):1285-94.
2006: Cecilia Cabrera; Bonaventura Clotet
[Resistance genotyping in patients with therapeutic failure].
Enfermedades infecciosas y microbiología clínica 2006;24(4):219-21.
2006: Anna Bonjoch; Roger Paredes; Pere Domingo; Manel Cervantes; Enric Pedrol; Esteban Ribera; Lluís Force; Josep M Llibre; Josep Vilaró; David Dalmau; Josep Cucurull; Jaume Mascaró; Angels Masabeu; Núria Pérez-Alvarez; Jordi Puig; Denise Cinquegrana; Bonaventura Clotet
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
AIDS research and human retroviruses 2006;22(4):321-9.
2006: Rika Draenert; Todd M Allen; Yang Liu; Terri Wrin; Colombe Chappey; Cori L Verrill; Guillem Sirera; Robert L Eldridge; Matthew P Lahaie; Lidia Ruiz; Bonaventura Clotet; Christos J Petropoulos; Bruce D Walker; Javier Martinez-Picado
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus.
The Journal of experimental medicine 2006;203(3):529-39.
2006: Mike Youle; Schlomo Staszweski; Bonaventura Clotet; José Ramon Arribas; Anders Blaxhult; Giampiero Carosi; Edwin DeJesus; Gianni Di Perri; Vicente Estrada; Martin Fisher; Colin Kovacs; Ranjababu Kulasegaram; Adriano Lazzarin; Debbie Marriott; Leopoldo Muñoz; Jacques Reynes; Peter Shalit; Jihad Slim; Christos M Tsoukas; Anthony Vaccaro; José Vera
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
HIV clinical trials 2006;7(2):86-96.
2006: Berta Bosch; Imma Clotet-Codina; Julià Blanco; Eduardo Pauls; Gemma Coma; Samandhy Cedeño; Francesc Mitjans; Anuska Llano; Margarita Bofill; Bonaventura Clotet; Jaume Piulats; José A Esté
Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody.
Antiviral research 2006;69(3):173-80.
2006: Eugenia Negredo; Bonaventura Clotet; Jordi Puig; Núria Pérez-Alvarez; Lidia Ruiz; Joan Romeu; José Moltó; Celestino Rey-Joly; Julià Blanco
The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.
AIDS (London, England) 2006;20(4):619-21.
2006: Sergi Purcet; Gerard Minuesa; Míriam Molina-Arcas; Itziar Erkizia; F Javier Casado; Bonaventura Clotet; Javier Martinez-Picado; Marçal Pastor-Anglada
3'-Azido-2',3'-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes.
Antiviral therapy 2006;11(6):803-11.
2006: Daniel Fuster; Ramon Planas; Juan Gonzalez; Lluís Force; Manel Cervantes; Josep Vilaró; Mercè Roget; Isabel García; Enric Pedrol; Jordi Tor; Angel Luis Ballesteros; Anna Salas; Guillem Sirera; Sebastián Videla; Bonaventura Clotet; Cristina Tural
Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
Antiviral therapy 2006;11(4):473-82.
2006: José Moltó; Lidia Ruiz; Marta Valle; Javier Martinez-Picado; Anna Bonjoch; Isabel Bravo; Eugenia Negredo; Gabrielle M Heilek-Sneider; Bonaventura Clotet
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Antiviral therapy 2006;11(1):47-51.
2006: Sònia López; Eugenia Negredo; Glòria Garrabou; Jordi Puig; Lidia Ruiz; Eduard Sanjurjo; Xavier Ramos; Ana B Infante; Jordi Casademont; Francesc Cardellach; Bonaventura Clotet; Oscar Miró
Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.
AIDS research and human retroviruses 2006;22(1):33-9.
2006: Rosario Sabariegos; Mireia Giménez-Barcons; Natalia Tàpia; Bonaventura Clotet; Miguel Angel Martínez
Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs.
Journal of virology 2006;80(2):571-7.
2005: Mercedes Armand-Ugón; Imma Clotet-Codina; Cristina Tintori; Fabrizio Manetti; Bonaventura Clotet; Maurizio Botta; José A Esté
The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.
Virology 2005;343(1):141-9.
2005: Amanda Mocroft; Vincent Soriano; Jürgen Rockstroh; Peter Reiss; Ole Kirk; Stephane de Wit; José M Gatell; Bonaventura Clotet; Andrew N Phillips; Jens D Lundgren
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
AIDS (London, England) 2005;19(18):2117-25.
2005: Mark Nelson; Keikawus Arastéh; Bonaventura Clotet; David A Cooper; Keith Henry; Christine Katlama; Jacob P Lalezari; Adriano Lazzarin; Julio S G Montaner; Mary E O'Hearn; Peter J Piliero; Jacques Reynes; Benoit Trottier; Sharon L Walmsley; Calvin Cohen; Joseph J Eron; Daniel R Kuritzkes; Joep Lange; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Neil E Buss; Lucille Donatacci; Cynthia Wat; Lynn Smiley; Martin Wilkinson; Adeline Valentine; Denise Guimaraes; Ralph DeMasi; Jain Chung; Miklos Salgo
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):404-12.
2005: Gemma Moncunill; Eugenia Negredo; Lluís Bosch; Jaume Vilarrasa; Myriam Witvrouw; Anuska Llano; Bonaventura Clotet; José A Esté
Evaluation of the anti-HIV activity of statins.
AIDS (London, England) 2005;19(15):1697-700.
2005: Victoria A Johnson; Françoise Brun Vezinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Amalio Telenti; Douglas D Richman
Update of the drug resistance mutations in HIV-1: Fall 2005.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2005;13(4):125-31.
2005: Berta Bosch; Julià Blanco; Eduardo Pauls; Imma Clotet-Codina; Mercedes Armand-Ugón; Boyan Grigorov; Delphine Muriaux; Bonaventura Clotet; Jean-Luc Darlix; José A Esté
Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
Antimicrobial agents and chemotherapy 2005;49(10):4296-304.
2005: Eugenia Negredo; Anna Bonjoch; Roger Paredes; Jordi Puig; Bonaventura Clotet
Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(6):901-5.
2005: Julià Blanco; Imma Clotet-Codina; Berta Bosch; Mercedes Armand-Ugón; Bonaventura Clotet; José A Esté
Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs.
Antimicrobial agents and chemotherapy 2005;49(9):3926-9.
2005: Julia G Prado; Neil Parkin; Bonaventura Clotet; Lidia Ruiz; Javier Martinez-Picado
HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(5):729-37.
2005: Daniel Fuster; Bonaventura Clotet
Review of atazanavir: a novel HIV protease inhibitor.
Expert opinion on pharmacotherapy 2005;6(9):1565-72.
2005: Natalia Tapia; Guerau Fernàndez; Mariona Parera; Gemma Gómez-Mariano; Bonaventura Clotet; Miguel E Quiñones-Mateu; Esteban Domingo; Miguel Angel Martínez
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection.
Virology 2005;338(1):1-8.
2005: Anna Bonjoch; Roger Paredes; Juan Galvez; Celia Miralles; Sebastián Videla; Eva Martínez; Jose Miranda; Jose Munoz-Moreno; Javier de la Torre; Arturo Prieto; Consuelo Vilades; Bonaventura Clotet
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
Journal of acquired immune deficiency syndromes (1999) 2005;39(3):313-6.
2005: Guillem Sirera; Sebastián Videla; Eva Castellá; Lluís Cavallé; Núria Grané; Mariona Llatjos; Cristina Tural; Eugenia Negredo; Angela Fernández; Celestino Rey-Joly; Bonaventura Clotet
[Contribution of human papillomavirus second-generation hybrid capture test for the diagnosis of cervical pathology in HIV-infected outpatients].
Medicina clínica 2005;125(4):127-31.
2005: Angel Luis Ballesteros; Daniel Fuster; Ramon Planas; Bonaventura Clotet; Cristina Tural
Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients.
The Journal of antimicrobial chemotherapy 2005;55(6):824-7.
2005: Javier Martinez-Picado; Terri Wrin; Simon D W Frost; Bonaventura Clotet; Lidia Ruiz; Andrew J Leigh Brown; Christos J Petropoulos; Neil Parkin
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
Journal of virology 2005;79(10):5907-13.
2005: Alain Pruvost; Eugenia Negredo; Henri BENECH; Frédéric Theodoro; Jordi Puig; Eulàlia Grau; Elisabet García; José Moltó; Jacques Grassi; Bonaventura Clotet
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 2005;49(5):1907-14.
2005: Mireia Giménez-Barcons; Meritxell Ribera; Anuska Llano; Bonaventura Clotet; José A Esté; Miguel Angel Martínez
Analysis of chemokine and cytokine expression in patients with HIV and GB virus type C coinfection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40(9):1342-9.
2005: Cecilia Cabrera; Bonaventura Clotet
[Mutations resulting in resistence of antiretroviral drugs in HIV-infected patients].
Medicina clínica 2005;124(16):618-9.
2005: Angeles Jaén; Jordi Casabona; Anna Esteve; José M Miró; Cristina Tural; Elena Ferrer; Melcior Riera; Ferran Segura; Lluís Force; Omar Sued; Josep Vilaró; Angels Masabeu; Isabel García; Esther Dorca; Jordi Altès; Gemma Navarro; Daniel Podzamczer; Concepción Villalonga; Bonaventura Clotet; José M Gatell
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project].
Medicina clínica 2005;124(14):525-31.
2005: Carmina R Fumaz; Jose Munoz-Moreno; José Moltó; Eugenia Negredo; Maria José Ferrer; Guillem Sirera; Núria Pérez-Alvarez; Guadalupe Gómez; David Burger; Bonaventura Clotet
Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
Journal of acquired immune deficiency syndromes (1999) 2005;38(5):560-5.
2005: Ana Barrios; Ana Rendón; Eugenia Negredo; Pablo Barreiro; Teresa Garcia-Benayas; Pablo Labarga; Jesús Santos; Pere Domingo; Matilde Sánchez Conde; Ivana Maida; Luz Martín-Carbonero; Marina Núñez; Francisco Blanco; Bonaventura Clotet; Maria Antonia Sambeat; Paloma Gil; Juan Gonzalez-Lahoz; David Cooper; Vincent Soriano
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
AIDS (London, England) 2005;19(6):569-75.
2005: Victoria A Johnson; Françoise Brun Vezinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Amalio Telenti; Douglas Richman
Update of the Drug Resistance Mutations in HIV-1: 2005.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2005;13(1):51-7.
2005: Margaret Johnson; L Nieto-Cisneros; A Horban; Keikawus Arastéh; J Gonzalez-Garcia; J G Artigas; Bonaventura Clotet; A Danise; R Landman; S Proll; W Snowden; R Foreman; P Smith
Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations.
HIV medicine 2005;6(2):107-13.
2005: Eugenia Negredo; Eva Martínez-López; Roger Paredes; Joaquim Rosales; Núria Pérez-Alvarez; Susana Holgado; Silvia Gel; Luís del Rio; Xavier Tena; Celestino Rey-Joly; Bonaventura Clotet
Reversal of HIV-1-associated osteoporosis with once-weekly alendronate.
AIDS (London, England) 2005;19(3):343-5.
2005: Daniel Fuster; Jaime A Huertas; Guadalupe Gómez; Ricard Solà; Juan González García; Josep Vilaró; Enric Pedrol; Lluís Force; Jordi Tor; Guillem Sirera; Sebastián Videla; Ramon Planas; Bonaventura Clotet; Cristina Tural
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.
Antiviral therapy 2005;10(7):841-7.
2005: Ana Barrios; Eugenia Negredo; Pere Domingo; Vicente Estrada; Pablo Labarga; Victor Asensi; Dolores Morales; Jesús Santos; Bonaventura Clotet; Vincent Soriano
Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Antiviral therapy 2005;10(7):825-32.
2005: Alessandro Cozzi-Lepri; Lidia Ruiz; Clive Loveday; Andrew N Phillips; Bonaventura Clotet; Peter Reiss; bruno ledergerber; Christian Holkmann; Schlomo Staszewski; Jens D Lundgren
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
Antiviral therapy 2005;10(7):791-802.
2005: Javier Martinez-Picado; Kristina Morales-Lopetegi; Cristina Villena; Carolina Gutiérrez; Nuria Izquierdo; Silvia Marfil; Bonaventura Clotet; Lidia Ruiz
Evidence for preferential genotyping of a minority human immunodeficiency virus population due to primer-template mismatching during PCR-based amplification.
Journal of clinical microbiology 2005;43(1):436-8.
2005: Eugenia Negredo; José Moltó; David Burger; Helene Côté; Oscar Miró; Josep Ribalta; Eva Martínez; Jordi Puig; Lidia Ruiz; Juliana Salazar; Sònia López; Julio Montaner; Celestino Rey-Joly; Bonaventura Clotet
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
Journal of acquired immune deficiency syndromes (1999) 2005;38(1):47-52.
2004: Julià Blanco; Berta Bosch; Maria Teresa Fernández-Figueras; Jordi Barretina; Bonaventura Clotet; José A Esté
High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells.
The Journal of biological chemistry 2004;279(49):51305-14.
2004: Angel Luis Ballesteros; Oscar Miró; Sònia López; Daniel Fuster; Sebastián Videla; Eva Martínez; Glòria Garrabou; Anna Salas; Helene Côté; Jordi Tor; Celestino Rey-Joly; Ramon Planas; Bonaventura Clotet; Cristina Tural
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Antiviral therapy 2004;9(6):969-77.
2004: Eugenia Negredo; Roger Paredes; Joaquim Peraire; Enric Pedrol; Helene Côté; Silvia Gel; Carmina R Fumoz; Lidia Ruiz; Vicente Abril; Eduardo Rodriguez de Castro; Claudia Ochoa; Javier Martinez-Picado; Julio Montaner; Celestino Rey-Joly; Bonaventura Clotet
Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.
Antiviral therapy 2004;9(6):889-93.
2004: Daniel Fuster; Ramon Planas; Roberto Muga; Angel Luis Ballesteros; Justiniano Santos; Jordi Tor; Guillem Sirera; Helena Guardiola; Anna Salas; Eduard Cabré; Isabel Ojanguren; Eva Barluenga; Celestino Rey-Joly; Bonaventura Clotet; Cristina Tural
Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
AIDS research and human retroviruses 2004;20(12):1293-7.
2004: José Moltó; Lidia Ruiz; Joan Romeu; Javier Martínez-Picado; Eugenia Negredo; Cristina Tural; Guillem Sirera; Bonaventura Clotet
Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.
AIDS research and human retroviruses 2004;20(12):1283-8.
2004: José A Iribarren; Pablo Labarga; Rafael Rubio; Juan Berenguer; José M Miró; Antonio Antela; Juan González; Santiago Moreno; Julio Arrizabalaga; Lourdes Chamorro; Bonaventura Clotet; José M Gatell; José López Aldeguer; Esteban Martínez; Rosa Polo; Montserrat Tuset; Pompeyo E. Viciana; Juan Miguel Santamaría; José María Kindelán; Esteban Ribera; Ferran Segura
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].
Enfermedades infecciosas y microbiología clínica 2004;22(10):564-642.
2004: Mariona Parera; Bonaventura Clotet; Miguel Angel Martinez
Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease.
Journal of virology 2004;78(24):14057-61.
2004: Margarita Bofill; E Almirall; Arthur McQuaid; Ruth Peña; Raul Ruiz-Hernandez; M Naranjo; Lidia Ruiz; Bonaventura Clotet; Francesc E Borras
Differential expression of the cytokine receptors for human interleukin (IL)-12 and IL-18 on lymphocytes of both CD45RA and CD45RO phenotype from tonsils, cord and adult peripheral blood.
Clinical and experimental immunology 2004;138(3):460-5.
2004: José Moltó; Bonaventura Clotet
Therapeutic drug monitoring of antiretroviral agents scenario.
Journal of HIV therapy 2004;9(4):75-8.
2004: Esteban Ribera; Rosa M Lopez; Marjorie Diaz; Leonor Pou; Lidia Ruiz; Vicenç Falcó; Manuel Crespo; Carlos Azuaje; Isabel Ruiz; Imma Ocaña; Bonaventura Clotet; Albert Pahissa
Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Antimicrobial agents and chemotherapy 2004;48(11):4256-62.
2004: Cristina Tural; Bonaventura Clotet
[The era of antiretroviral therapy... and the era of hepatitis C virus coinfection].
Medicina clínica 2004;123(12):460-2.
2004: Cecilia Cabrera; Alessandro Cozzi-Lepri; Andrew N Phillips; Clive Loveday; Ole Kirk; Mounir Ait-Khaled; Peter Reiss; Jesper Kjaer; bruno ledergerber; Jens D Lundgren; Bonaventura Clotet; Lidia Ruiz
Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Antiviral therapy 2004;9(5):787-800.
2004: Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Richard T D'Aquila; Lisa M Demeter; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Amalio Telenti; Douglas D Richman
Update of the drug resistance mutations in HIV-1: 2004.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2004;12(4):119-24.
2004: Julià Blanco; Jordi Barretina; Bonaventura Clotet; José A Esté
R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
Journal of leukocyte biology 2004;76(4):804-11.
2004: Jordi Barretina; Julià Blanco; Anna Bonjoch; Anuska Llano; Bonaventura Clotet; José A Esté
Immunological and virological study of enfuvirtide-treated HIV-positive patients.
AIDS (London, England) 2004;18(12):1673-82.
2004: Julia G Prado; Sandra Franco; Tania Matamoros; Lidia Ruiz; Bonaventura Clotet; Luis Menéndez-Arias; Miguel Angel Martínez; Javier Martinez-Picado
Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
Virology 2004;326(1):103-12.
2004: Eduardo Fernandez-Cruz; Santiago Moreno; J Navarro; Bonaventura Clotet; Emilio Bouza; JAVIER CARBONE; Jose Peña; J Pérez Molina; Daniel Podzamczer; R Rubio; Imma Ocaña; Federico Pulido; Pompeyo E. Viciana; J A Maradona; R Blazquez; C Barros; C Quereda; C Rodriguez-Sainz; Juana Gil; M L Abad; L Díaz; C Cantó; M A Muñoz; E Ferrer; Antoni Jou; Guillem Sirera; M Díaz; F Lopez; José M Gatell; J Gonzalez-Lahoz
Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.
Vaccine 2004;22(23-24):2966-73.
2004: Françoise Brun-Vézinet; Dominique Costagliola; Mounir Ait Khaled; Vincent Calvez; François Clavel; Bonaventura Clotet; Richard Haubrich; Dale J Kempf; Marty King; Daniel R Kuritzkes; Randall Lanier; M Miller; Veronica Miller; Andrews Phillips; Deenan Pillay; Jonathan M Schapiro; Janna Scott; Robert Shafer; Maurizio Zazzi; Andrew R Zolopa; Victor DeGruttola
Clinically validated genotype analysis: guiding principles and statistical concerns.
Antiviral therapy 2004;9(4):465-78.
2004: Bonaventura Clotet
Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.
AIDS reviews 2004;6(3):123-30.
2004: Eugenia Negredo; José Moltó; Jose Munoz-Moreno; Enric Pedrol; Esteban Ribera; Pompeyo E. Viciana; M José Galindos; Celia Miralles; David Burger; Carmina Rodriguez Fumaz; Jordi Puig; Silvia Gel; Eva Rodríguez; Sebastián Videla; Lidia Ruiz; Bonaventura Clotet
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Antiviral therapy 2004;9(3):335-42.
2004: Bonaventura Clotet; François Raffi; David Cooper; Jean-François Delfraissy; Adriano Lazzarin; Graeme Moyle; Jürgen Rockstroh; Vincent Soriano; Jonathan Schapiro
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.
AIDS (London, England) 2004;18(8):1137-46.
2004: Roger Paredes; Bonaventura Clotet
[Duration of antiretroviral combinations].
Medicina clínica 2004;122(18):696-7.
2004: Mariona Parera; Angela Ibañez; Bonaventura Clotet; Miguel Angel Martinez
Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy.
The Journal of infectious diseases 2004;189(8):1444-51.
2004: Julia G Prado; Ayumi Shintani; Margarita Bofill; Bonaventura Clotet; Lidia Ruiz; Javier Martinez-Picado
Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptions.
Journal of clinical microbiology 2004;42(4):1620-5.
2004: Eugenia Negredo; Josep Ribalta; Raimon Ferré; Juliana Salazar; Celestino Rey-Joly; Guillem Sirera; Luis Masana; Bonaventura Clotet
Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.
AIDS (London, England) 2004;18(5):819-21.
2004: Bonaventura Clotet
Comparison of regimens as initial therapy for HIV.
The New England journal of medicine 2004;350(10):1053-4; author reply 1053-4.
2004: Eugenia Negredo; José Moltó; David Burger; Pompeyo E. Viciana; Esteban Ribera; Roger Paredes; Manel Juan; Lidia Ruiz; Jordi Puig; Alain Pruvost; Jacques Grassi; Elisabeth Masmitjà; Bonaventura Clotet
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
AIDS (London, England) 2004;18(3):459-63.
2004: Angel Luis Ballesteros; Sandra Franco; Daniel Fuster; Ramon Planas; Miguel Angel Martínez; Lesly Acosta; Guillem Sirera; Anna Salas; Jordi Tor; Celestino Rey-Joly; Bonaventura Clotet; Cristina Tural
Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
AIDS (London, England) 2004;18(1):59-66.
2004: Bonaventura Clotet; Jorge Carmena; Federico Pulido; Isabel Luque; Felipe Rodriguez-Alcántara
Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients.
HIV clinical trials 2004;5(1):33-9.
2003: Sharon Walmsley; Keith Henry; Christine Katlama; Mark Nelson; Antonella Castagna; Jacques Reynes; Bonaventura Clotet; James Hui; Miklos Salgo; Ralph DeMasi; John Delehanty
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
The Journal of infectious diseases 2003;188(12):1827-33.
2003: Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Richard T D'Aquila; Lisa M Demeter; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Amalio Telenti; Douglas D Richman
Drug resistance mutations in HIV-1.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2003;11(6):215-21.
2003: Lidia Ruiz; Esteban Ribera; Anna Bonjoch; Joan Romeu; Javier Martinez-Picado; Roger Paredes; Marjorie Díaz; Silvia Marfil; Eugenia Negredo; Julia García-Prado; Cristina Tural; Guillem Sirera; Bonaventura Clotet
Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.
The Journal of infectious diseases 2003;188(7):977-85.
2003: Bonaventura Clotet; Marc van der Valk; Eugenia Negredo; Peter Reiss
Impact of nevirapine on lipid metabolism.
Journal of acquired immune deficiency syndromes (1999) 2003;34 Suppl 1():S79-84.
2003: Fernando Laguna; Sebastián Videla; Manuel E Jiménez-Mejías; Guillem Sirera; Julián Torre-Cisneros; Esteban Ribera; Dolores Prados; Bonaventura Clotet; Mariano Sust; Rogelio López-Vélez; Jorge Alvar
Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
The Journal of antimicrobial chemotherapy 2003;52(3):464-8.
2003: Amanda Mocroft; Lidia Ruiz; Peter Reiss; bruno ledergerber; Christine Katlama; Adriano Lazzarin; Frank-Detlef Goebel; Andrew N Phillips; Bonaventura Clotet; Jens D Lundgren
Virological rebound after suppression on highly active antiretroviral therapy.
AIDS (London, England) 2003;17(12):1741-51.
2003: Jan Weber; Hector Rangel; Bikram Chakraborty; Mahlet Tadele; Miguel A Martinez; Javier Martinez-Picado; Michael L Marotta; Muneer Mirza; Lidia Ruiz; Bonaventura Clotet; Terri Wrin; Christos J Petropoulos; Miguel E Quiñones-Mateu
A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy.
The Journal of general virology 2003;84(Pt 8):2217-28.
2003: Jordi Barretina; J Juncà; Anuska Llano; Arantxa Gutiérrez; A Flores; Julià Blanco; Bonaventura Clotet; José A Esté
CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease.
Annals of hematology 2003;82(8):500-5.
2003: Javier Martinez-Picado; Eugenia Negredo; Lidia Ruiz; Ayumi Shintani; Carmina R Fumaz; Carlos Zala; Pere Domingo; Josep Vilaró; Josep M Llibre; Pompeyo E. Viciana; Kurt Hertogs; Charles Boucher; Richard T D'Aquila; Bonaventura Clotet
Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.
Annals of internal medicine 2003;139(2):81-9.
2003: Carmina R Fumaz; Bonaventura Clotet
Assessment of changes in adherence and quality of life after the simplification of antiretroviral treatment.
IAPAC monthly 2003;9(7):145, 165.
2003: Mercedes Armand-Ugón; Arantxa Gutiérrez; Bonaventura Clotet; José A Esté
HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.
Antiviral research 2003;59(2):137-42.
2003: Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Douglas D Richman
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2003;11(4):150-4.
2003: Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Donna M Jacobsen; Douglas D Richman
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(1):113-28.
2003: Adriano Lazzarin; Bonaventura Clotet; David Cooper; Jacques Reynes; Keikawus Arastéh; Mark Nelson; Christine Katlama; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Joep Lange; Les Huson; Ralph DeMasi; Cynthia Wat; John Delehanty; Claude Drobnes; Miklos Salgo
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
The New England journal of medicine 2003;348(22):2186-95.
2003: Catherine Fagard; Annette Oxenius; Huldrych Günthard; Felipe Garcia; Michelle Le Braz; Gabriel Mestre; Manuel Battegay; Hansjakob Furrer; Pietro Vernazza; Enos Bernasconi; Amalio Telenti; Rainer Weber; Dominique Leduc; Sabine Yerly; David Price; Sara J Dawson; Thomas Klimkait; Thomas V Perneger; Angela McLean; Bonaventura Clotet; José M Gatell; Luc Perrin; Montserrat Plana; Rodney Phillips; Bernard Hirschel
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Archives of internal medicine 2003;163(10):1220-6.
2003: Remko van Leeuwen; Christine Katlama; Robert L Murphy; Kathleen E Squires; José M Gatell; Andrzej Horban; Bonaventura Clotet; Shlomo Staszewski; Arne van Eeden; Nathan Clumeck; Mauro Moroni; Andrew T Pavia; Reinhold E Schmidt; Juan Gonzalez-Lahoz; Julio Montaner; Francisco Antunes; Roy M Gulick; Dénes Bánhegyi; Marc van der Valk; Peter Reiss; Liesbeth van Weert; Frank van Leth; Victoria A Johnson; Jean-Pierre Sommadossi; Joep M A Lange
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
AIDS (London, England) 2003;17(7):987-99.
2003: Richard T D'Aquila; Jonathan M Schapiro; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Lisa M Demeter; Robert M Grant; Victoria A Johnson; Daniel R Kuritzkes; Clive Loveday; Robert W Shafer; Douglas D Richman
Drug resistance mutations in HIV-1.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2003;11(3):92-6.
2003: Miguel Angel Martinez; Bonaventura Clotet
Genetic screen for monitoring hepatitis C virus NS3 serine protease activity.
Antimicrobial agents and chemotherapy 2003;47(5):1760-5.
2003: Daniel Fuster; Bonaventura Clotet
Chronic HCV infection in HIV-positive patients: a new challenge.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2003;2(2):56-8.
2003: Jordi Barretina; Julià Blanco; Mercedes Armand-Ugón; Arantxa Gutiérrez; Bonaventura Clotet; José A Esté
Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
Antiviral therapy 2003;8(2):155-61.
2003: Alessandro Cozzi-Lepri; Andrew N Phillips; Veronica Miller; Christine Katlama; bruno ledergerber; STEFANO VELLA; Jonathan Weber; Johan Bruun; Ole Kirk; Bonaventura Clotet; Jens D Lundgrens
Changes in viral load in people with virological failure who remain on the same HAART regimen.
Antiviral therapy 2003;8(2):127-36.
2003: Anuska Llano; Jordi Barretina; Arantxa Gutiérrez; Bonaventura Clotet; José A Esté
Interleukin-7-dependent production of RANTES that correlates with human immunodeficiency virus disease progression.
Journal of virology 2003;77(7):4389-95.
2003: Cristina Tural; Daniel Fuster; Jordi Tor; Isabel Ojanguren; Guillem Sirera; Angel Luis Ballesteros; J A J Lasanta; Ramon Planas; Celestino Rey-Joly; Bonaventura Clotet
Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients.
Journal of viral hepatitis 2003;10(2):118-25.
2003: Natàlia Tàpia; Sandra Franco; FRANCESC PUIG-BASAGOITI; Clara Menéndez; Pedro L Alonso; Hassan Mshinda; Bonaventura Clotet; Juan Carlos Saiz; Miguel Angel Martínez
Influence of human immunodeficiency virus type 1 subtype on mother-to-child transmission.
The Journal of general virology 2003;84(Pt 3):607-13.
2003: Mercedes Armand-Ugón; Miguel E Quiñones-Mateu; Arantxa Gutiérez; Jordi Barretina; Julià Blanco; Dominique Schols; Erik De Clercq; Bonaventura Clotet; José A Esté
Reduced fitness of HIV-1 resistant to CXCR4 antagonists.
Antiviral therapy 2003;8(1):1-8.
2003: Julià Blanco; Jordi Barretina; Karine F Ferri; Etienne Jacotot; Arantxa Gutiérrez; Mercedes Armand-Ugón; Cecilia Cabrera; Guido Kroemer; Bonaventura Clotet; José A Esté
Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events.
Virology 2003;305(2):318-29.
2003: Roger Paredes; Bonaventura Clotet
New antiretroviral drugs and approaches to HIV treatment.
AIDS (London, England) 2003;17 Suppl 4():S85-96.
2003: Bonaventura Clotet; Eugenia Negredo
HIV protease inhibitors and dyslipidemia.
AIDS reviews 2003;5(1):19-24.
2002: Miguel Angel Martínez; Arantxa Gutiérrez; Mercedes Armand-Ugón; Julià Blanco; Mariona Parera; Jordi Gómez; Bonaventura Clotet; José A Esté
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication.
AIDS (London, England) 2002;16(18):2385-90.
2002: Miguel Angel Martínez; Bonaventura Clotet; José A Esté
RNA interference of HIV replication.
Trends in immunology 2002;23(12):559-61.
2002: Javier Martinez-Picado; Simon D W Frost; Nuria Izquierdo; Kristina Morales-Lopetegi; Silvia Marfil; Teresa Puig; Cecilia Cabrera; Bonaventura Clotet; Lidia Ruiz
Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals.
Journal of virology 2002;76(23):12344-8.
2002: José Manuel Egea; Roberto Muga; Guillem Sirera; Bonaventura Clotet; Jordi Tor; M Ardèvol; Celestino Rey-Joly; ALVARO MUNOZ
Initiation, changes in use and effectiveness of highly active anti-retroviral therapy in a cohort of injecting drug users.
Epidemiology and infection 2002;129(2):325-33.
2002: Oscar Gallego; Lidia Ruíz; Alex Vallejo; Bonaventura Clotet; Manuel Leal; Vincent Soriano
Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain.
Journal of clinical microbiology 2002;40(10):3865-6.
2002: Miguel E Quiñones-Mateu; Mahlet Tadele; Mariona Parera; Antonio Mas; Jan Weber; Hector Rangel; Bikram Chakraborty; Bonaventura Clotet; Esteban Domingo; Luis Menéndez-Arias; Miguel A Martínez
Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.
Journal of virology 2002;76(20):10546-52.
2002: Mounir Ait-Khaled; Chris Stone; Gillian Amphlett; Bonaventura Clotet; Schlomo Staszewski; Christine Katlama; Margaret Tisdale
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
AIDS (London, England) 2002;16(12):1686-9.
2002: Marta Cabana; Guerau Fernàndez; Mariona Parera; Bonaventura Clotet; Miguel Angel Martínez
Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions.
Virology 2002;300(1):71-8.
2002: Veronica Miller; Andrew N Phillips; Bonaventura Clotet; Amanda Mocroft; bruno ledergerber; Ole Kirk; Vidar Ormaasen; Panagiotis Gargalianos-Kakolyris; STEFANO VELLA; Jens D Lundgren
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.
The Journal of infectious diseases 2002;186(2):189-97.
2002: Eugenia Negredo; Josep Ribalta; Roger Paredes; Raimon Ferré; Guillem Sirera; Lidia Ruiz; Juliana Salazar; Peter Reiss; Luis Masana; Bonaventura Clotet
Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
AIDS (London, England) 2002;16(10):1383-9.
2002: Felipe García; Bonaventura Clotet; Santiago Moreno; Juan Carlos López Bernaldo De Quirós; José M Gatell
[Treatment interruptions in clinical practice].
Enfermedades infecciosas y microbiología clínica 2002;20 Suppl 2():68-73.
2002: Bonaventura Clotet; Lidia Ruiz; Javier Martinez-Picado; Eugenia Negredo; Andrew Hill; Matei Popescu
Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.
HIV clinical trials 2002;3(4):316-23.
2002: Julia G Prado; Terri Wrin; Jeff Beauchaine; Lidia Ruiz; Christos J Petropoulos; Simon D W Frost; Bonaventura Clotet; Richard T D'Aquila; Javier Martinez-Picado
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
AIDS (London, England) 2002;16(7):1009-17.
2002: Javier Martinez-Picado; Kristina Morales-Lopetegi; Terri Wrin; Julia G Prado; Simon D W Frost; Christos J Petropoulos; Bonaventura Clotet; Lidia Ruiz
Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions.
AIDS (London, England) 2002;16(6):895-9.
2002: Amanda Mocroft; Andrew N Phillips; N Friis-Møller; Robert Colebunders; A M Johnson; Bernard Hirschel; T Saint-Marc; T Staub; Bonaventura Clotet; Jens D Lundgren
Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study.
Antiviral therapy 2002;7(1):21-30.
2002: Carmina R Fumaz; Albert Tuldrà; Maria José Ferrer; Roger Paredes; Anna Bonjoch; Toni Jou; Eugenia Negredo; Joan Romeu; Guillem Sirera; Cristina Tural; Bonaventura Clotet
Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.
Journal of acquired immune deficiency syndromes (1999) 2002;29(3):244-53.
2002: Eugenia Negredo; Luís Cruz; Roger Paredes; Lidia Ruiz; Carmina R Fumaz; Anna Bonjoch; Silvia Gel; Albert Tuldrà; Montserrat Balagué; Susan Johnston; Albert Arno; Antoni Jou; Cristina Tural; Guillem Sirera; Joan Romeu; Bonaventura Clotet
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(4):504-10.
2002: Simon D W Frost; Javier Martinez-Picado; Lidia Ruiz; Bonaventura Clotet; Andrew J Leigh Brown
Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection.
Journal of virology 2002;76(3):968-79.
2002: Cristina Tural; Lidia Ruiz; Christopher Holtzer; Jonathan Schapiro; Pompeyo E. Viciana; Juan González; Pere Domingo; Charles Boucher; Celestino Rey-Joly; Bonaventura Clotet
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.
AIDS (London, England) 2002;16(2):209-18.
2002: Roger Paredes; Juan Carlos López Benaldo de Quirós; Eduardo Fernández-Cruz; Bonaventura Clotet; H Clifford Lane
The potential role of interleukin-2 in patients with HIV infection.
AIDS reviews 2002;4(1):36-40.
2002: Julià Blanco; Jordi Barretina; Arantxa Gutiérrez; Mercedes Armand-Ugón; Cecilia Cabrera; Bonaventura Clotet; José A Esté
Preferential attachment of HIV particles to activated and CD45RO+CD4+ T cells.
AIDS research and human retroviruses 2002;18(1):27-38.
2002: Cecilia Cabrera; Arantxa Gutiérrez; Jordi Barretina; Julià Blanco; Alexander Litovchick; Aviva Lapidot; Bonaventura Clotet; José A Esté
Anti-HIV activity of a novel aminoglycoside-arginine conjugate.
Antiviral research 2002;53(1):1-8.
2001: Marc van der Valk; John J P Kastelein; Robert L Murphy; Frank van Leth; Christine Katlama; Andrzej Horban; M Glesby; G Behrens; Bonaventura Clotet; R K Stellato; H O Molhuizen; Peter Reiss
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
AIDS (London, England) 2001;15(18):2407-14.
2001: Andrew N Phillips; Christian Pradier; Adriano Lazzarin; Bonaventura Clotet; Frank-Detlef Goebel; P Hermans; Francisco Antunes; bruno ledergerber; Ole Kirk; Jens D Lundgren
Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients.
AIDS (London, England) 2001;15(18):2385-95.
2001: Anuska Llano; Jordi Barretina; Arantxa Gutiérrez; Julià Blanco; Cecilia Cabrera; Bonaventura Clotet; José A Esté
Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals.
Journal of virology 2001;75(21):10319-25.
2001: Albert Tuldrà; Carmina R Fumaz; Maria José Ferrer; Roger Paredes; Joan Romeu; Lidia Ruiz; Ramon Bayés; Bonaventura Clotet
Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads.
AIDS (London, England) 2001;15(14):1904-6.
2001: Anuska Llano; Jordi Barretina; Julià Blanco; Arantxa Gutiérrez; Bonaventura Clotet; José A Esté
Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo.
AIDS (London, England) 2001;15(14):1890-2.
2001: Julià Blanco; Jordi Barretina; Cecilia Cabrera; Arantxa Gutiérrez; Bonaventura Clotet; José A Esté
CD4(+) and CD8(+) T cell death during human immunodeficiency virus infection in vitro.
Virology 2001;285(2):356-65.
2001: Lidia Ruiz; Eugenia Negredo; Pere Domingo; Roger Paredes; E Francia; Montserrat Balagué; Silvia Gel; Anna Bonjoch; Carmina R Fumaz; Susan Johnston; Joan Romeu; J Lange; Bonaventura Clotet
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
Journal of acquired immune deficiency syndromes (1999) 2001;27(3):229-36.
2001: Lidia Ruiz; G Carcelain; Javier Martínez-Picado; S Frost; Silvia Marfil; Roger Paredes; Joan Romeu; E Ferrer; Kristina Morales-Lopetegi; B Autran; Bonaventura Clotet
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.
AIDS (London, England) 2001;15(9):F19-27.
2001: Ole Kirk; Amanda Mocroft; C Pradier; JN Bruun; R Hemmer; Bonaventura Clotet; Veronica Miller; Jean-Paul Viard; Andrew N Phillips; Jens D Lundgren
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
AIDS (London, England) 2001;15(8):999-1008.
2001: E Casado; Alejandro Olivé; Susana Holgado; R Perez-Andres; Joan Romeu; J C Lorenzo; Bonaventura Clotet; Xavier Tena
Musculoskeletal manifestations in patients positive for human immunodeficiency virus: correlation with CD4 count.
The Journal of rheumatology 2001;28(4):802-4.
2001: A Ibáñez; Bonaventura Clotet; Miguel Angel Martínez
Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy.
Virology 2001;282(1):1-5.
2001: Anne-Mieke Vandamme; F Houyez; D Bànhegyi; Bonaventura Clotet; G De Schrijver; Koen De Smet; W W Hall; R Harrigan; N Hellmann; Kurt Hertogs; C Holtzer; Brendan Larder; D Pillay; E Race; Jean-Claude Schmit; R Schuurman; E Schulse; Anders Sönnerborg; V Miller
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up.
Antiviral therapy 2001;6(1):21-39.
2001: José M Gatell; José L Blanco; José Alcamí; Antonio Antela; Julio Arrizabalaga; J L Casado; Bonaventura Clotet; R Delgado; Alejo Erice; Luis Guerra; A Guerrero; José A Iribarren; M Leal; J C López; Luis Menéndez-Arias; José M Miró; Santiago Moreno; JL Pérez; Tomás Pumarola; Rafael Rubio; L Ruiz; Juan Miguel Santamaría; V Soriano; A Telenti; Pompeyo E. Viciana
[GESIDA Consensus document on the use of resistance studies in clinical practice].
Enfermedades infecciosas y microbiología clínica 2001;19(Monografico):53-60.
2001: Antonio Antela; José A Iribarren; Bonaventura Clotet; L Guerra
[Consensus documents and clinical guidelines on resistance to antiretroviral agents].
Enfermedades infecciosas y microbiología clínica 2001;19(Monografico):47-52.
2001: Christine Katlama; Bonaventura Clotet; Andreas Plettenberg; J Jost; Keikawus Arastéh; E Bernasconi; V Jeantils; Amy Cutrell; Chris Stone; S Purdon
Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
HIV medicine 2001;2(1):27-34.
2000: Albert Tuldrà; Carmina R Fumaz; Maria José Ferrer; Ramon Bayés; Albert Arno; Montserrat Balagué; Anna Bonjoch; Antoni Jou; Eugenia Negredo; Roger Paredes; Lidia Ruiz; Joan Romeu; Guillem Sirera; Cristina Tural; David Burger; Bonaventura Clotet
Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2000;25(3):221-8.
2000: José M Miró; Antonio Antela; Julio Arrizabalaga; Bonaventura Clotet; José M Gatell; Luis Guerra; J Antonio Iribarren; Fernando Laguna; Santiago Moreno; Francisco Parras; Rafael Rubio; Juan Miguel Santamaría; Pompeyo E. Viciana
[Recommendations of GESIDA (Grupo de Estudio de SIDA)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (II)].
Enfermedades infecciosas y microbiología clínica 2000;18(8):396-412.
2000: Felipe García; M M Alonso; Joan Romeu; Hernando Knobel; Julio Arrizabalaga; Elena Ferrer; David Dalmau; I Ruiz; Francesc Vidal; A Frances; Ferran Segura; JL Gomez-Sirvent; Anna Cruceta; Bonaventura Clotet; Tomás Pumarola; Teresa Gallart; WA O'Brien; José M Miró; José M Gatell
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
Journal of acquired immune deficiency syndromes (1999) 2000;25(1):26-35.
2000: José M Miró; Antonio Antela; Julio Arrizabalaga; Bonaventura Clotet; José M Gatell; Luis Guerra; José A Iribarren; Fernando Laguna; Santiago Moreno; Francisco Parras; Rafael Rubio; Juan Miguel Santamaría; Pompeyo E. Viciana
[Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)].
Enfermedades infecciosas y microbiología clínica 2000;18(7):329-51.
2000: Kristien Van Vaerenbergh; Kristel Van Laethem; J Albert; C A Boucher; Bonaventura Clotet; Marco Floridia; J Gerstoft; B Hejdeman; C Nielsen; Christophe Pannecouque; L Perrin; Maria F Pirillo; Lidia Ruiz; Jean-Claude Schmit; F Schneider; A Schoolmeester; R Schuurman; Hans-Jürgen Stellbrink; Lieven Stuyver; Jan van Lunzen; Barbara Van Remoortel; Eric Van Wijngaerden; STEFANO VELLA; Myriam Witvrouw; S Yerly; Erik De Clercq; J Destmyer; Anne-Mieke Vandamme
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.
Antimicrobial agents and chemotherapy 2000;44(8):2109-17.
2000: Kristel Van Laethem; Jean-Claude Schmit; H Pelemans; Jan Balzarini; Myriam Witvrouw; María-Jesús Pérez-Pérez; María-José Camarasa; Robert M Esnouf; Stefano Aquaro; Alessandra Cenci; Carlo Federico Perno; Philippe Hermans; S Sprecher; Lidia Ruiz; Bonaventura Clotet; Eric Van Wijngaerden; Marc Van Ranst; Jan Desmyter; Erik De Clercq; Anne-Mieke Vandamme
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
AIDS research and human retroviruses 2000;16(9):825-33.
2000: Amanda Mocroft; Veronica Miller; Antonio Chiesi; Anders Blaxhult; Christine Katlama; Bonaventura Clotet; S Barton; Jens D Lundgren
Virological failure among patients on HAART from across Europe: results from the EuroSIDA study.
Antiviral therapy 2000;5(2):107-12.
2000: Martin S Hirsch; Françoise Brun-Vézinet; Richard T D'Aquila; Scott M Hammer; Victoria A Johnson; Daniel R Kuritzkes; Clive Loveday; John W Mellors; Bonaventura Clotet; Brian Conway; Lisa M Demeter; STEFANO VELLA; Donna M Jacobsen; Douglas D Richman
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2000;283(18):2417-26.
2000: Christine Katlama; Bonaventura Clotet; Andreas Plettenberg; J Jost; Keikawus Arastéh; E Bernasconi; V Jeantils; Amy Cutrell; Chris Stone; Mounir Ait-Khaled; S Purdon
The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
AIDS (London, England) 2000;14(7):781-9.
2000: Mireia Giménez-Barcons; Alberto Sánchez-Fueyo; Sergi Ampurdanés; FRANCESC PUIG-BASAGOITI; Magda Guilera; A Ibáñez; Bonaventura Clotet; Miguel Angel Martínez; Juan Rodés; Juan Carlos Saiz; José M Sánchez-Tapias
Genetic evolution of GB virus C/hepatitis G virus (GBV-C/HGV) under interferon pressure.
Antiviral research 2000;46(2):157-70.
2000: Cecilia Cabrera; Arantxa Gutiérrez; Julià Blanco; Jordi Barretina; Alexander Litovchick; Aviva Lapidot; AG Evdokimov; Bonaventura Clotet; José A Esté
Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.
AIDS research and human retroviruses 2000;16(7):627-34.
2000: Miguel Angel Martínez; Marta Cabana; Mariona Parera; A Gutierrez; José A Esté; Bonaventura Clotet
A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease.
Antimicrobial agents and chemotherapy 2000;44(5):1132-9.
2000: R Paredes; A Mocroft; Ole Kirk; A Lazzarin; S E Barton; J van Lunzen; T L Katzenstein; F Antunes; J D Lundgren; Bonaventura Clotet
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
Archives of internal medicine 2000;160(8):1123-32.
2000: T Puig; Mayte Pérez-Olmeda; A Rubio; Lidia Ruiz; Carlos Briones; J M Franco; M Gómez-Cano; Lieven Stuyver; L Zamora; C Alvarez; Manuel Leal; Bonaventura Clotet; V Soriano
Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.
AIDS (London, England) 2000;14(6):727-32.
2000: Kristien Van Vaerenbergh; Kristel Van Laethem; Eric Van Wijngaerden; Jean-Claude Schmit; F Schneider; Lidia Ruiz; Bonaventura Clotet; Chris Verhofstede; Filip Van Wanzeele; Gaëtan Muyldermans; P Simons; Lieven Stuyver; Philippe Hermans; C Evans; Erik De Clercq; Jan Desmyter; Anne-Mieke Vandamme
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
AIDS research and human retroviruses 2000;16(6):529-37.
2000: Kristel Van Laethem; Myriam Witvrouw; Jan Balzarini; Jean-Claude Schmit; S Sprecher; Philippe Hermans; M Leal; Thomas Harrer; Lidia Ruiz; Bonaventura Clotet; Marc Van Ranst; Jan Desmyter; Erik De Clercq; Anne-Mieke Vandamme
Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir.
AIDS (London, England) 2000;14(4):469-71.
2000: Lidia Ruiz; Javier Martinez-Picado; Joan Romeu; Roger Paredes; MK Zayat; Silvia Marfil; Eugenia Negredo; Guillem Sirera; Cristina Tural; Bonaventura Clotet
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
AIDS (London, England) 2000;14(4):397-403.
2000: José L Casado; Kurt Hertogs; Lidia Ruiz; Fernando Dronda; A Van Cauwenberge; Albert Arno; I Garcia-Arata; Stuart Bloor; Anna Bonjoch; J Blazquez; Bonaventura Clotet; Brendan Larder
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
AIDS (London, England) 2000;14(2):F1-7.
2000: FRANCESC PUIG-BASAGOITI; M Cabana; Magda Guilera; Mireia Giménez-Barcons; Guillem Sirera; Cristina Tural; Bonaventura Clotet; José M Sánchez-Tapias; Juan Rodés; Juan Carlos Saiz; Miguel Angel Martínez
Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV.
Journal of acquired immune deficiency syndromes (1999) 2000;23(1):89-94.
2000: A Ibáñez; Bonaventura Clotet; Miguel Angel Martínez
Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies.
The Journal of general virology 2000;81(Pt 1):85-95.
2000: Julià Blanco; Jordi Barretina; Geoffrey Henson; Gary J Bridger; Erik De Clercq; Bonaventura Clotet; José A Esté
The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis.
Antimicrobial agents and chemotherapy 2000;44(1):51-6.
1999: Felipe García; Joan Romeu; Imma Grau; Maria Antonia Sambeat; David Dalmau; Hernando Knobel; JL Gomez-Sirvent; Julio Arrizabalaga; Anna Cruceta; Bonaventura Clotet; Daniel Podzamczer; Tomás Pumarola; Teresa Gallart; WA O'Brien; José M Miró; José M Gatell
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
AIDS (London, England) 1999;13(17):2377-88.
1999: Marta Cabana; Bonaventura Clotet; Miguel Angel Martínez
Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.
Journal of medical virology 1999;59(4):480-90.
1999: C Cabrera; M Witvrouw; A Gutiérrez; Bonaventura Clotet; Mirjam E Kuipers; Pieter J Swart; Dirk K F Meijer; Jan Desmyter; Erik De Clercq; José A Esté
Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4.
AIDS research and human retroviruses 1999;15(17):1535-43.
1999: Roger Paredes; Teresa Puig; Albert Arno; Eugenia Negredo; Montserrat Balagué; Anna Bonjoch; Antoni Jou; Albert Tuldrà; Cristina Tural; Guillem Sirera; A Veny; Joan Romeu; Lidia Ruiz; Bonaventura Clotet
High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.
Journal of acquired immune deficiency syndromes (1999) 1999;22(2):132-8.
1999: José A Esté; C Cabrera; Julià Blanco; A Gutierrez; Gary J Bridger; Geoffrey Henson; Bonaventura Clotet; Dominique Schols; Erik De Clercq
Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
Journal of virology 1999;73(7):5577-85.
1999: Albert Arno; Lidia Ruiz; Manel Juan; Antoni Jou; Montserrat Balagué; MK Zayat; Silvia Marfil; Javier Martínez-Picado; M A Martínez; Joan Romeu; Ricardo Pujol Borrell; C Lane; Bonaventura Clotet
Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with
The Journal of infectious diseases 1999;180(1):56-60.

1999: Albert Tuldrà; Maria José Ferrer; Carmina R Fumaz; Ramon Bayés; R Paredes; David Burger; Bonaventura Clotet
Monitoring adherence to HIV therapy.
Archives of internal medicine 1999;159(12):1376-7.
1999: Angela Ibáñez; T Puig; J Elias; Bonaventura Clotet; Lidia Ruiz; M A Martínez
Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.
AIDS (London, England) 1999;13(9):1045-9.
1999: Julià Blanco; Etienne Jacotot; C Cabrera; A Cardona; Bonaventura Clotet; Erik De Clercq; José A Esté
The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling.
AIDS (London, England) 1999;13(8):909-17.
1999: M A Martínez; M Cabana; Angela Ibáñez; Bonaventura Clotet; Albert Arno; Lidia Ruiz
Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia.
Virology 1999;256(2):180-7.
1999: Julià Blanco; C Cabrera; A Jou; L Ruiz; Bonaventura Clotet; José A Esté
Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy.
AIDS (London, England) 1999;13(5):547-55.
1999: L Ruiz; Jan van Lunzen; A Arno; Hans-Jürgen Stellbrink; C Schneider; Miquel Rull; Eva Castellà; Isabel Ojanguren; D D Richman; Bonaventura Clotet; Klara Tenner-Racz; Paul Racz
Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue.
AIDS (London, England) 1999;13(1):F1-8.
1999: Eugenia Negredo; Roger Paredes; Anna Bonjoch; Albert Tuldrà; Carmina R Fumaz; Silvia Gel; B Garcés; Susan Johnston; Albert Arno; Montserrat Balagué; Antoni Jou; Cristina Tural; Guillem Sirera; Joan Romeu; L Cruz; E Francia; Pere Domingo; Julio Arrizabalaga; I Ruiz; José R Arribas; Lidia Ruiz; Bonaventura Clotet
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Antiviral therapy 1999;4 Suppl 3():23-8.
1999: M Gómez-Cano; A Rubio; Lidia Ruiz; Mayte Pérez-Olmeda; Manuel Leal; Bonaventura Clotet; Vincent Soriano
Efficiency of drug resistance genotypic tests in specimens with low HIV viral load.
Antiviral therapy 1999;4(2):123-4.
1999: A Rubio; M Gómez-Cano; T Puig; Manuel Leal; Mayte Pérez-Olmeda; Lidia Ruiz; Bonaventura Clotet; C Rey; L Zamora; N Xaus; V Soriano
Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
Antiviral therapy 1999;4(1):45-9.
1999: José A Esté; C Cabrera; Erik De Clercq; Sofie Struyf; J Van Damme; Gary J Bridger; Renato T Skerlj; M J Abrams; Geoffrey Henson; A Gutierrez; Bonaventura Clotet; Dominique Schols
Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor.
Molecular pharmacology 1999;55(1):67-73.
1998: Jean-Claude Schmit; Kristel Van Laethem; Lidia Ruiz; Philippe Hermans; S Sprecher; Anders Sönnerborg; M Leal; Thomas Harrer; Bonaventura Clotet; Vic Arendt; E Lissen; Myriam Witvrouw; Jan Desmyter; Erik De Clercq; Anne-Mieke Vandamme
Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.
AIDS (London, England) 1998;12(15):2007-15.
1998: Santiago Moreno; Julio Arrizabalaga; José M Gatell; Bonaventura Clotet; Koldo Aguirrebengoa; Antonio Antela; José A Iribarren; Fernando Laguna; José M Miró; Imma Ocaña; R Rubio; Pompeyo E. Viciana; Daniel Podzamczer
[Recommendations for antiretroviral treatment in 1998. AIDS Working Group of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)].
Enfermedades infecciosas y microbiología clínica 1998;16(8):374-6.
1998: Jose A Este; Bonaventura Clotet
HIV phenotype & genotype data highlights Lake Maggiore meeting.
Journal of the International Association of Physicians in AIDS Care 1998;4(9):60-3.
1998: Lidia Ruiz; Monique Nijhuis; C Boucher; Teresa Puig; Anna Bonjoch; Javier Martínez-Picado; Silvia Marfil; D de Jong; David Burger; Albert Arno; Montserrat Balagué; Bonaventura Clotet
Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;19(1):19-28.
1998: A Ibáñez; Mireia Giménez-Barcons; A Tajahuerce; Cristina Tural; Guillem Sirera; Bonaventura Clotet; José M Sánchez-Tapias; Juan Rodés; Miguel Angel Martínez; Juan Carlos Saiz
Prevalence and genotypes of GB virus C/hepatitis G virus (GBV-C/HGV) and hepatitis C virus among patients infected with human immunodeficiency virus: evidence of GBV-C/HGV sexual transmission.
Journal of medical virology 1998;55(4):293-9.
1998: C Vidal; Felipe García; Joan Romeu; L Ruiz; José M Miró; Anna Cruceta; A Soriano; Tomás Pumarola; Bonaventura Clotet; José M Gatell
Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection.
AIDS (London, England) 1998;12(11):1285-9.
1998: Jean-Claude Schmit; Lidia Ruiz; Lieven Stuyver; Kristel Van Laethem; I Vanderlinden; T Puig; Rudi Rossau; Jan Desmyter; Erik De Clercq; Bonaventura Clotet; Anne-Mieke Vandamme
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.
Journal of virological methods 1998;73(1):77-82.
1998: Martin S Hirsch; Brian Conway; Richard T D'Aquila; Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Lisa M Demeter; Scott M Hammer; Donna M Jacobsen; Daniel R Kuritzkes; Clive Loveday; John W Mellors; STEFANO VELLA; Douglas D Richman
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.
JAMA : the journal of the American Medical Association 1998;279(24):1984-91.
1998: M Gómez-Cano; A Rubio; T Puig; Mayte Pérez-Olmeda; Lidia Ruiz; V Soriano; J A Pineda; L Zamora; N Xaus; Bonaventura Clotet; Manuel Leal
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
AIDS (London, England) 1998;12(9):1015-20.
1998: Joan Romeu; Montserrat Balagué; L Ruiz; Silvia Marfil; Teresa Puig; Albert Arno; A Veny; Cristina Tural; Guillem Sirera; Bonaventura Clotet
[Value of HIV-1 viral load and CD4 lymphocyte count as determinants of progression to AIDS and survival].
Medicina clínica 1998;110(20):761-7.
1998: Albert Arno; Lidia Ruiz; Manel Juan; MK Zayat; Teresa Puig; Montserrat Balagué; Joan Romeu; R Pujol; WA O'Brien; Bonaventura Clotet
Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years.
AIDS (London, England) 1998;12(7):697-704.
1998: Cristina Tural; Joan Romeu; Guillem Sirera; D Andreu; M Conejero; S Ruiz; Antoni Jou; Anna Bonjoch; Lidia Ruiz; Albert Arno; Bonaventura Clotet
Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.
The Journal of infectious diseases 1998;177(4):1080-3.
1998: Andrew N Phillips; C Katlama; S Barton; STEFANO VELLA; Anders Blaxhult; Bonaventura Clotet; F D Goebel; Bernard Hirschel; C Pedersen; J D Lundgren
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;17(3):239-44.
1998: S Moreno; Julio Arrizabalaga; José M Gatell; Bonaventura Clotet; Koldo Aguirrebengoa; A Antela; José A Iribarren; Fernando Laguna; José M Miró; Imma Ocaña; R Rubio; Pompeyo E. Viciana; Daniel Podzamczer
[Recommendations on antiretroviral treatment. The AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology].
Medicina clínica 1998;110(3):109-16.
1997: R Paredes; F Laguna; Bonaventura Clotet
Leishmaniasis in HIV-infected persons: a review.
Journal of the International Association of Physicians in AIDS Care 1997;3(6):22-39.
1997: A Ibáñez; Joaquim Peraire; Albert Arno; C Gutiérrez; M Cervantes; J Colomer; C Villalonga; Miguel Camafort Babkowski; Lidia Ruiz; MD Balaguer; F Vidal; C Richart; Bonaventura Clotet
Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
Antiviral therapy 1997;2(2):105-11.
1996: Lidia Ruiz; Joan Romeu; Angela Ibáñez; C Cabrera; T Puig; M A Morales; Guillem Sirera; Bonaventura Clotet
Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
Antiviral therapy 1996;1(4):220-4.
1996: Lidia Ruiz; Joan Romeu; Javier Martínez-Picado; Jean-Claude Schmit; Anne-Mieke Vandamme; Montserrat Balagué; C Cabrera; T Puig; Cristina Tural; A Segura; Guillem Sirera; E De Clercq; Bonaventura Clotet
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
AIDS (London, England) 1996;10(14):F61-6.
1996: Lidia Ruiz; Joan Romeu; Bonaventura Clotet; Montserrat Balagué; C Cabrera; Guillem Sirera; Angela Ibáñez; Javier Martínez-Picado; A Raventós; Cristina Tural; A Segura; M Foz
Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300 x 10(6)/l.
AIDS (London, England) 1996;10(11):F39-44.
1996: Bonaventura Clotet; Lidia Ruiz; C Cabrera; Angela Ibáñez; M P Cañadas; Guillem Sirera; Joan Romeu; J Vila
Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
Antiviral therapy 1996;1(3):189-93.
1996: Jean-Claude Schmit; Lidia Ruiz; Bonaventura Clotet; A Raventos; J Tor; J Leonard; Jan Desmyter; E De Clercq; Anne-Mieke Vandamme
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).
AIDS (London, England) 1996;10(9):995-9.
1996: Beatriz Bayés; Joan Romeu; M Vaquero; M Ribera; José-Tomás Navarro; A Rosell; Guillem Sirera; Bonaventura Clotet
[Disseminated histoplasmosis and AIDS. Report of 4 cases].
Medicina clínica 1996;106(18):700-3.
1996: O Estrada; Joan Romeu; G Giménez; A Raventós; Guillem Sirera; Bonaventura Clotet
[Bronchogenic carcinoma in patients with human immunodeficiency virus infection].
Medicina clínica 1996;106(17):661-4.
1991: Joan Romeu; F Millà; Montserrat Batlle; Guillem Sirera; C Ferrandiz; A Carreres; M J Condom; Bonaventura Clotet
Visceral leishmaniasis involving lung and a cutaneous Kaposi's sarcoma lesion.
AIDS (London, England) 1991;5(10):1272.
1991: Bonaventura Clotet; Guillem Sirera; Joan Romeu; J M Gimeno; Antoni Jou; M J Condom; J Tor; M Foz
Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis.
AIDS (London, England) 1991;5(5):601-2.
1990: J Tor; J M Llibre; M Carbonell; Roberto Muga; A Ribera; V Soriano; Bonaventura Clotet; M Sabriá; M Foz
Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV.
BMJ (Clinical research ed.) 1990;301(6761):1130-3.
1990: Guillem Sirera; Fuensanta Millá; M J Condom; Bonaventura Clotet
[Asymptomatic visceral leishmaniasis in a patient with acquired immunodeficiency syndrome].
Medicina clínica 1990;94(5):196.
1989: M J Condom; Bonaventura Clotet; Guillem Sirera; F Milla; M Foz
Asymptomatic leishmaniasis in the acquired immunodeficiency syndrome (AIDS)
Annals of internal medicine 1989;111(9):767-8.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.